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The aim of this project is to study whether Regulatory T cells (Treg) 
influence remyelination following a demyelinating insult of the central 
nervous system (CNS). Recent studies have shown that biopsies of 
demyelinated lesions taken from Multiple Sclerosis (MS) patients contain 
Treg 1. They can also be observed in sites of inflammation within the CNS 
of mice with Experimental Autoimmune Encephalomyelitis (EAE), a 
model of MS in which CNS inflammation is induced in animals. Since 
these cells are found in sites of demyelination and secrete a number of 
cytokines known to affect oligodendrocyte precursor cell (OPC) and 
oligodendrocyte cell function (Table 1), it is important to understand if 
and how they influence repair mechanisms such as remyelination.  
I have studied the effect that cytokines secreted by Treg have on OPC 
biology. I have approached this two ways: first by adding conditioned 
media from in vitro primary cultures of Treg to in vitro primary cultures 
of OPCs, to study the effects of a full complement of Treg-secreted 
cytokines on OPCs, and second by choosing the candidate molecule 
Leukaemia inhibitory factor (LIF), delivered directly to OPCs using 
nanoparticles.  Studies in the past have similarly analysed the effects of 
single cytokines on OPC behaviour and morphology 2,3 and conditioned 
media from other T cell types have been added to microglia 4.  
In the future, this work will be extended to studying the effect of Treg 
and LIF nanoparticles in mouse brain slices ex vivo and in an in vivo 
mouse model of demyelination. 
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1.1.1 Structure of Myelin 
 
Axons larger than about 1μm in diameter in the mammalian 
nervous system are wrapped in a fatty membrane known as 
myelin. Myelin has several important functions which include the 
provision of trophic support to axons5,32 and increasing the rate of 
axonal conduction. Structurally, myelin is made from multiple 
layers of plasma membrane, tightly bound to one another by 
transmembrane proteins such as proteolipid protein (PLP). In the 
human peripheral nervous system, myelin is produced by 
Schwann cells that each wrap around a single axon, and in the 
central nervous system (CNS) by oligodendrocytes (OLs) which 
each can form multiple myelin sheaths around different axons. 
Oligodendrocyte cells are post-mitotic, and, under normal 
conditions, have great longevity. When forming a new myelin 
sheath, each oligodendrocyte process first contacts an 
unmyelinated section of an axon. Following contact, the process 
extends laterally along an axon and finally extends around the 
axon forming a continuous spiral of plasma membrane filled with 
myelin proteins. Some of these proteins, such as PLP and myelin 
basic protein (MBP), maintain the structure of the myelin sheath 
through cross-linking between layers of membrane (see Fig. 1, 
adapted from 6,7). Proteins such as MBP in the intracellular space 
of the myelin sheath create the ‘major dense lines’ observed on 
electron micrograph images of myelin. Genetic ablation of MBP 
causes a severe and fatal hypomyelination phenotype in mice, the 
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so-called ‘shiverer’ mouse 8,9. On the other hand, mice that lack 
PLP show no symptoms other  
 
 
than slightly less compact, but still fully functional, myelin 10. This is in 
contrast to mutation 11-13 or over-expression 14,15 of PLP which is 
consistently detrimental in mice and humans. These studies seem to 
show that while MBP is a non-redundant component of myelin structure, 
other proteins are not essential for proper myelin sheath assembly. 
 
 
1.1.2 Oligodendrocytes  
 
Oligodendrocytes arise from oligodendrocyte precursor cells 
(OPCs) in the ventral ventricular zone of the developing brain and 
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spinal cord. Sonic hedgehog (Shh) signalling acts to pattern tissue 
in this area (for review see 16) and initiates the expression of two 
transcription factors that direct cells to the oligodendrocyte 
lineage; Olig1 and Olig2 17,18. Ectopic expression of Shh elsewhere 
in the spinal cord leads to ectopic development of OPCs 19. The 
expression of Olig1/2 in turn leads to the expression of other early 
glial cell lineage transcription factors such as Sox10 20 and Nkx2.2 
21,22 which are required for differentiation of oligodendrocytes. 
OPCs were first identified as a population of bi-potential glial 
progenitors resident in the perinatal rat optic nerve, and so called 
O-2A cells for their ability to develop either into oligodendrocytes 
(O) or type-II astrocytes (2A) 23. Later, so-called ‘adult’ O-2A cells 
were discovered in adult optic nerve, demonstrating that they 
persist into adult life in the mammalian CNS 24. In the adult brain, 
these adult OPCs persist as a population of dividing cells that, 
despite only making up 5-8% of adult brain cells 25, represent 70% 
of proliferating cells as labelled by BrdU pulses in the adult brain 
26. They are identified by expression of the surface markers platelet 
derived growth factor receptor alpha (PDGFRa) and chondroitin 
sulphate proteoglycan (NG2). NG2+ glial cells have many 
processes, which are highly branched, and are found in a 
continuous network throughout the CNS 27. They express AMPA 
receptors, are capable of synaptic communication with neurons 28 
and have been observed forming synapses with unmyelinated 
axons in the corpus callosum 29, although why they should be 
sensitive to axonal signalling is unclear. Although myelination 
occurs in late prenatal and early postnatal stages in mammalian 
brain, adult OPCs still generate oligodendrocytes in the adult CNS 
and studies have shown that 20% of oligodendrocytes are 
generated after 7 weeks of age in mice 30. It has also been shown 
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that in models of CNS inflammation 31 and focal demyelination 32 
OPCs can respond by proliferating and migrating to the damaged 
area before forming new oligodendrocytes, indicating a system of 
repair and regeneration. 
 
1.1.3 Benefits of myelination 
 
Myelin sheaths are separated from each other along an axon by 
small unmyelinated segments, known as Nodes of Ranvier. 
Oligodendrocytes induce the clustering of Nav1.2 voltage-gated 
sodium channels (VGSCs) at these nodes 33 during development 
which are later replaced by Nav1.6 VGSCs 34,35. Clustering is 
dependent on an as-yet unidentified soluble factor 33. Following 
experimental ablation of oligodendrocytes and demyelination, 
sodium channel clustering disappears within 1 week, whereas if 
viable oligodendrocytes remain in the vicinity, clustering can 
persist for up to 8 weeks 36. This is probably due to the preservation 
of soluble signals from oligodendrocytes. Ultimately, restoration of 
myelin sheaths is required for nodal re-organisation, which shows 
similarities to developmental myelination in that Nav1.2 expression 
precedes Nav1.6 expression 36. The surface of the axon located 
beneath a myelin sheath, or internodal region, is separated from the 
axonal surface at Nodes of Ranvier by the paranodes, assembled by 
transmembrane proteins such as CASPR, contactin and neurofascin 
155, on the axonal and oligodendrocyte membranes, which form a 
diffusion barrier, and aid organisation of the Node 37 (for review 
see 38). These proteins anchor the edges of the myelin sheath to the 
axonal membrane and maintain a high concentration of VGSCs in 
the node. This structural arrangement allows electrical insulation of 
the axon. The myelin sheath, with its multiple layers of membrane, 
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increases the capacitance of the axon to the extent that charge 
travels along the axon in a series of leaps between nodes rather 
than flowing through the axonal cytoplasm. This conduction via 
local circuits between nodes, known as saltatory conduction, is an 
order of magnitude faster than conduction through the axon itself. 
Following the destruction of myelin sheaths (demyelination), it has 
been shown that the regeneration of myelin sheaths around nerve 
axons, a process known as remyelination, can restore the 
conduction of electrical signals, by restoring the structural 
arrangement 39. 
As well as allowing rapid nerve conduction, myelination by 
oligodendrocytes also provides trophic support to axons and 
protects against axonal degeneration. Two recent studies show that 
oligodendrocytes supply axons with energy in the form of lactate. 
The first study shows that oligodendrocytes shuttle lactate to axons 
through the myelin sheath 5. The second shows that the lactate 
transporter monocarboxylate transporter 1 (MCT1) is enriched in 
oligodendrocytes, and that reducing the level of MCT1 translation 
in oligodendrocytes in vivo leads to axonal degeneration 40. This 
lends support to the hypothesis that myelination or remyelination 
prevent axonal degeneration in demyelinating diseases such 
multiple sclerosis (MS). Evidence for this hypothesis includes the 
PLPnull mouse, in which oligodendrocytes are capable of forming 
apparently structurally-normal myelin, yet axonal degeneration is 
observed 41. The same is true of the myelin-associated glycoprotein-
null (MAGnull) mouse 42, despite this protein having a relatively 
minor role in the assembly of the myelin sheath. Finally, deletion of 
the oligodendrocyte population by expressing the diphtheria toxin 
(DT) receptor in PLP-expressing cells prior to DT application, also 
leads to axonal degeneration 43. Taken together, these studies 
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1.2 Multiple sclerosis 
 
1.2.1 Symptoms and pathology 
 
MS is an autoimmune neurodegenerative disorder that is the 
second most common cause of disability amongst young adults in 
the UK after traumatic injury 44. It carries a lifetime risk of 1 in 400 
and has an incidence of 120 per 100,000 people 45. Scotland has the 
world’s highest prevalence of MS with 1 in 500 people suffering 
from the disease 46. Despite decades of research, the initial trigger 
for the disease is unclear although pathology is thought to be 
driven by self-reactive T lymphocytes accumulating in the CNS. 
Disease onset often occurs between 20 and 40 years of age and the 
most common symptoms of the disease are cognitive, motor and 
sensory defects. Disease course commonly takes one of three main 
patterns. The most common pattern of MS, affecting 80% of MS 
patients, is ‘relapsing-remitting’ MS. This consists of periods of 
‘relapses’ with clinical symptoms followed by periods of almost 
complete recovery, termed ‘remissions’. Many of these patients 
convert to ‘secondary progressive’ MS, where their symptoms 
gradually worsen even during remission despite few or no 
relapses. In ‘primary progressive’ MS, clinical symptoms become 
steadily worse over time without any relapses. It is thought that 
relapses are caused by episodes of transient inflammation of the 
CNS, with concomitant demyelination.  
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The pathology seen in MS consists of plaques or ‘demyelinated 
lesions’ in the white matter in the brain and spinal cord, often 
associated closely with blood vessels, with oligodendrocyte 
damage or destruction, demyelination and axon degeneration. The 
loss of the myelin sheath around axon processes leads to loss of 
nerve function in these areas and the associated symptoms of the 
disease. Pathologists categorise lesions according to levels of active 
inflammation, demyelination and regeneration. Lesions are 
commonly referred to by this method as chronic, active, chronic-
active or ‘remyelinated’ in which myelin sheaths have been partly 
replaced. Initially, early in the course of MS, lesions repair and 
remyelinate, but over time this fails and the damage becomes 
chronic. It has been found that capacity for repair reduces with the 
age of the patient 47,48. It has been hypothesised, on the basis of 
animal studies as described above where myelin is required for 
axonal health, that demyelination (and failure of remyelination) 
makes axons vulnerable to axonal degeneration. It is hard to prove 
a causative link from pathological study of MS tissue; however it is 
known that axonal damage is positively correlated with increasing 
disability 49. Furthermore, in a mouse model of chronic CNS 
inflammation, experimental autoimmune encephalomyelitis (EAE), 
axonal degeneration is greatest in areas of acute demyelination and 
remyelinated areas have no significant axonal damage 50. The most 
persuasive evidence that remyelination protects axons is a study in 
which mice were fed dietary cuprizone, a copper chelator which is 
toxic for oligodendrocytes, and axonal loss was quantified under 
different conditions. Mice were treated with cuprizone to globally 
demyelinate the CNS and either X-irradiated to kill OPCs and 
inhibit remyelination 51 or left to remyelinate normally. Normal 
remyelination resulted in reduced axonal loss in this model, albeit 
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in the absence of autoimmune inflammation 52. These studies taken 
together suggest that remyelination is protective and that boosting 
the process of remyelination could be therapeutic in patients with 
MS. 
 
1.2.2 Risk factors in MS 
 
In pairs of monozygotic twins in which one twin suffers from MS 
the chance that the second twin will also develop MS is 26% 53. This 
is in comparison to the risk for first-degree relatives of 3-4% and a 
general population risk of 0.1-0.2% 54, suggesting a significant 
contribution of genetic factors to lifetime risk. Further support for 
the heritability of MS risk comes from studies of adopted and 
biological siblings of MS sufferers. These show that having a sibling 
with MS increases lifetime risk in biological siblings whereas 
adopted siblings had a risk comparable to the general population, 
suggesting that genetic factors are more important than 
environmental factors 54. Through GWAS studies, increasingly 
more gene loci have been discovered which associate with MS risk 
55,56. Almost all these genes are associated with the immune system, 
with the greatest risk imparted by alleles in the human leukocyte 
antigen (HLA) class II genes, located on chromosome 6 57. These 
genes code for antigen-presenting proteins that bind peptides 
within cells and travel to the cell surface where the peptides are 
displayed to immune cells. There are three classes of HLA class II 
protein complexes, named DP, DQ and DR, and each is a 
combination of two peptide chains. Due to the great diversity 
required to recognise potential threats, there is great variability in 
the HLA protein loci. Many HLA alleles are inherited together in 
haplotypes and it is the extended HLA ‘DR15’ haplotype of three 
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alleles - DRB1*1501, DQA1*0102 and DQB1*0602 - that carries the 
greatest risk of MS. Homozygosity for this haplotype increases 
lifetime risk six-fold 58. Other haplotypes, such as DR3 and DR4, 
have been shown to increase risk but to a lesser extent than DR15 
59.  
 
Epidemiological studies have also suggested a number of 
environmental factors that influence an individual’s lifetime risk of 
MS. Among these, it has been shown that the incidence of MS 
appears to increase in temperate climates, with increased distance 
from the equator. Subjects moving to another climate earlier than, 
approximately, the age of 15, assume the lifetime risk of their new 
region. Those moving after 15 years maintain the risk from the 
place where they grew up; hinting that development early in life 
determines a subject’s lifetime risk of MS 60. Environmental factors 
such as diet are also thought to contribute to MS risk. In particular, 
vitamin D deficiency, possibly accounting for the increase in 
incidence at high latitudes due to lower UV radiation levels 60, has 
been put forward as an important risk factor. A recent study 
showing that mutations in a protein involved in vitamin-D 
metabolism increase MS risk provides strong evidence in support 
of this association. In a cohort of Canadian MS patients, with a 
strong history of MS in the family, a variant in the CYP27B1 gene 
was enriched. This variant causes inactivation of 25-
hydroxyvitamin D-1α hydroxylase, which converts 25-
hydroxyvitamin D-1α to active vitamin D, leading to vitamin D 
deficiency 61. Individuals who are homozygous for this rare allele 
suffer from a genetic form of the bone disease Rickets, whereas the 
study found that heterozygous individuals had an increased risk of 
developing MS. Studies aiming to correlate lifetime vitamin D 
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levels with the chance of being diagnosed with MS also provide 
evidence for a link. In a study including a total of 182,000 nurses, 
the consumption of supplemental vitamin D was correlated with a 
40% lower risk of developing MS 62. In another study, the health 
records of active US army personnel were used to estimate each 
individual’s serum vitamin D levels. Over the course of the study, 
those in the highest quintile of vitamin D levels were 62% less 
likely to develop MS than those in the lowest 63. The growing 
number of similar studies that associate vitamin D levels with 
decreased risk of MS has led to calls for mandatory dietary vitamin 
D supplementation in at-risk populations 57. 
 
The greatest, and perhaps most well-known, risk factor for MS is 
infection with Epstein-Barr virus (EBV), which causes glandular 
fever. In most people, infection is at an early age and 
asymptomatic. However, some adults survive to adulthood with 
negative serum titres of immunoglobulin G (IgG) antibodies 
against the latent EBV protein anti-EBV nuclear antigen 1 (EBNA-
1), which is the main marker for immunity to EBV. First infection at 
adolescence or adulthood can cause a more serious disease, 
infectious mononucleosis (often referred to as ‘Mono’), which has a 
number of symptoms including high fever, fatigue and 
lymphadenopathy57. Among those who have a medical history of 
infectious mononucleosis, who are assumed to have avoided 
exposure to EBV in childhood, the incidence of MS was increased 
by two to three times 64. Another study of more than 8 million US 
army recruits showed that only 5% were negative for EBV 
antibodies when they were recruited. Of this cohort, 10 later 
developed MS and all of these individuals had suffered from 
infectious mononucleosis a few months prior to developing MS 65. 
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This study supports the hypothesis that primary exposure to EBV 
relatively late in life may significantly increase MS risk. EBV infects 
B-cells and has modulatory effects on the immune system and this 
has been suggested as a possible mechanism for any causative role 
in MS.  
 
 
1.2.3  Experimental models of Multiple Sclerosis 
 
The chronic nature of the disease and complex interaction of the 
adaptive immune and nervous systems over time have made MS a 
difficult disease to model, especially as there is no natural animal 
model of the disease. There are good model systems that can 
recapitulate the various immune and degenerative aspects of MS 
but not usually in combination. The most commonly used animal 
models of MS can be divided into predominantly immune-
mediated and toxin-induced which each have their advantages and 
disadvantages in different situations depending on the research 
question. 
 
Experimental autoimmune encephalomyelitis 
This is an autoimmune disease of mice initiated by immunisation 
with one of a number of myelin proteins. First developed in 
primates 66, EAE is commonly induced with MBP and MOG 
peptides emulsified in adjuvant, such as complete Freund’s 
adjuvant (CFA). This provides the inflammatory insult required to 
prime the immune system, allowing T cells that are specific for the 
particular peptide used to be activated and target myelin sheaths. 
This model may accurately recapitulate the CNS inflammation 
typical of MS and can produce a disease course with a monophasic 
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course (similar to a relapse), or several relapses, or even, with the 
Biozzi mouse model, a progressive neurodegenerative phase, 
depending on the experimental induction protocol and the strain or 
species of animal used. EAE may be very useful for analysing the 
immune responses that take place in CNS autoimmune disease and 
has been used to demonstrate both the requirement for Treg in 
resolving CNS autoimmune inflammation 67 and that injection of 
Tg4 Treg specific for the Ac1-9 MBP peptide (see methods) can 
ameliorate EAE induced with the same peptide and can help to 
reduce the recovery time in EAE induced with a peptide from a 
different myelin protein (PLP) 68. While EAE is obviously very 
good at examining the roles that different T cell types play in 
development, maintenance and recovery of CNS autoimmune 
inflammation, it does not, for the most part, model the process of 
remyelination as well. Therefore, in order to study remyelination, 
we must use a different model, one that does not have the added 
variable of CNS inflammation.  
 
Cuprizone-induced demyelination 
One aspect of MS that is not modelled well in EAE is the re-
myelination of demyelinated axons following oligodendrocyte 
death. This process restores the myelin sheath to axons and 
facilitates recovery. There are several ways of modelling this 
behaviour experimentally. One method is by using the Cuprizone 
model of demyelination. Cuprizone is a copper chelator that causes 
widespread death of mature oligodendrocytes when fed orally to 8-
week old mice. The selectivity for oligodendrocytes is thought to be 
a result of the enormous metabolic demands placed on these cells 
by the formation and maintenance of myelin sheaths and this 
makes them particularly vulnerable to the effects of this toxin. 
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Cuprizone administered orally over 1-2 weeks effectively 
demyelinates the CNS and, following removal of the toxin from the 
diet of the mouse, remyelination begins after around 4 days 69,70. 
This model effectively models demyelination and subsequent 
remyelination, but the insult occurs throughout the CNS rather 
than in the distinct lesions observed in chronic MS, and there is 
some toxic axonal damage noted as well. 
 
Lysophosphatidyl choline-induced white matter lesions 
Lysophosphatidyl choline (LPC), also known as Lysolecithin, is 
used to produce focal demyelinated lesions. LPC is a detergent 
molecule that emulsifies lipids and therefore causes damage to 
phospholipid membranes 71. The huge surface membrane area to 
cell body volume ratio of oligodendrocytes ensures that at low 
doses this toxin preferentially targets these cells, with little non-
specific damage to surrounding cells. In vivo, these lesions are 
induced through stereotaxic injection of LPC into a specific area of 
the CNS, causing localised demyelination and inflammation. In 
rodents these lesions fully remyelinate over the course of four 
weeks and can be used to model the demyelination and 
remyelination in focal lesions without the complication of an on-
going immune reaction and inflammation (as in EAE). It is also 
possible to apply LPC to ex vivo slices of mouse brain, producing a 
useful in vitro model of demyelinated tissue. 
 
All of these systems model specific aspects of MS pathology but fall 
short of modelling the disease as a whole. As such they 
complement each other but more chronic variants of these 
experiments would be extremely useful for probing the chronic 
pathology of MS. I have chosen to use LPC lesions for the in vivo 
19 
experiments in this project as this will allow examination of how 
Treg influence remyelination in the absence of neural 
inflammation, a variable that I wish to exclude in order to test the 
direct effects of Treg on oligodendroglial cells rather than indirect 





1.3.1 Oligodendrocyte precursor cells 
 
Remyelination is the regenerative process, known since the early 
1960s 72, through which missing or damaged myelin sheaths are 
replaced by OPCs 73. These OPCs are multipotent progenitor cells 
found throughout the CNS that are able to proliferate and migrate 
and can differentiate into mature myelin-forming 
oligodendrocytes, as well as astrocytes 31 and they have been 
reported to occasionally form Schwann cells 32 and neurons 30,31. 
OPCs are identified through the expression of the cell surface 
marker proteins NG2 (a chondroitin sulphate proteoglycan) and 
alpha-type platelet-derived growth factor receptor (pdgfr) 74. As 
they develop from simple uni- or bi-polar OPCs, they successively 
express the marker proteins NG2, O4 sulphatide (O4) and finally 
MBP as they mature into post-mitotic oligodendrocytes (Fig. 2) that 
are typically highly branched with many membranous processes. 
These processes contact demyelinated axons and extend a sheath 
around the axon that is subsequently filled with myelin proteins 
and extends laterally along the axonal membrane. This process is 
distinct from  
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developmental myelination in that it occurs against a background 
of oligodendrocyte cell death that has left an axon without a myelin 
sheath and in an inflammatory environment. In order for each OPC 
to successfully remyelinate a demyelinated axon it must first 
survive the initial insult, then migrate to the site of injury, 
proliferate and finally differentiate from a small, mobile OPC into a 
large membranous oligodendrocyte: a process requiring huge 
amounts of protein synthesis and energy expenditure.  
 
1.3.2 Challenges to remyelination 
 
Remyelination is inefficient In MS patients: not all lesions 
remyelinate equally. In some patients, remyelination can be 
relatively complete and relatively poor in others 75. A number of 
theories have been put forward as an explanation for this including 
depletion of OPCs from lesioned areas, the stalling of OPC 
differentiation and OPC migration failure (for review see 76). In 
rodents, at least, OPCs effectively repopulate areas that have been 
depleted of OPCs in vivo 77 and repeated demyelination of the 
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same area does not affect the frequency of OPCs in the lesioned 
area long-term and does not prevent subsequent remyelination 78. 
In contrast, a failure of differentiation as a remyelination-blocking 
mechanism is supported by studies of lesions, some of which show 
a sufficiency of OPCs that apparently fail to differentiate 79. A 
possible explanation for this is that the environment of the lesion is 
not supportive of proper oligodendrocyte differentiation. Often, as 
in MS, tissue damage and inflammation produce a complex milieu 
of proteins in the environment around the site of damage that can 
either enhance or inhibit remyelination. For example it has been 
shown that mice lacking tumour necrosis factor-alpha (TNF-/-) 
have much slower remyelination in the CNS. In these TNF-/- mice 
78.4% of axons in the corpus callosum remain demyelinated 2 
weeks after a demyelinating ‘cuprizone’ diet is withdrawn, 
compared to 11% in wild-type controls 2. Many other cytokines 
including interleukin-2 (IL-2) 80 and interferon-gamma (IFN) 81 
have been shown to have an effect on oligodendroglial cells, often 
inhibitory (see Table 1). An added challenge is the finding that, in 
rats at least, greater age decreases the ability of OPCs to 
remyelinate axons 82. This is due both to deficits in differentiation 
and in recruitment to damaged areas 83. This is consistent with 
research that shows that remyelination of MS lesions is less 
complete in autopsy tissue from patients with chronic MS, who are 
older, compared with tissue from diagnostic biopsies of newly-
diagnosed MS, who are younger 84. Inhibition of remyelination-
promoting proteins by age-related DNA changes has also been 
implicated in decreasing remyelination efficiency with age 85. 
Recent studies also suggest that excess hyaluronan in lesion sites 
blocks OPC maturation. Examining lesions from patients suffering 
from MS and mice with EAE shows that astrocytes secrete 
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hyaluronan that builds up in lesions and inhibits OPC 
differentiation 86. Further work has shown that hyaluronidases 
expressed by oligodendrocytes first digest high molecular weight 
(HMW) hyaluronan and that low molecular weight (LMW) 
hyaluronan is the molecule that blocks differentiation, acting 
through toll-like receptor 2 (TLR2) 87. The protein LINGO-1 has 
also been shown to inhibit remyelination in lesions. Antibodies 
blocking this protein boost remyelination in a rodent model of focal 
demyelination 88. The use of these antibodies has also been 
suggested as a therapy for MS in humans 89. Myelin debris has also 
been shown to inhibit oligodendrocyte maturation 90, further 
establishing that demyelinated lesions are often not permissive to 
repair.  
 
1.3.3 Histological markers of remyelination 
 
The histological markers of remyelinated axons are typically 
thinner than expected myelin sheaths and shorter internodes. This 
can be seen on sections of lesioned CNS tissue stained with a luxol 
fast-blue (LFB) stain. Remyelinated lesions stain blue, just as 
normal white matter does, however the shade of blue is paler, 
which is a sign of reduced myelin sheath thickness. These plaques 
are known as ‘shadow plaques’ as a result. Myelin sheath thickness 
in a healthy adult conforms to a tightly controlled relationship 
between axon diameter and myelin thickness, described by the ‘G 
ratio’: the ratio of the diameter of the axon alone to the total 
diameter of the axon and myelin sheath. In the human nervous 
system, myelin thickness increases with axon diameter in a 
proportional relationship. It has been suggested that a value of 0.6 
is the theoretical optimum value of axon diameter to myelin 
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thickness in the healthy nerve 91. The actual observed ratio is 
between 0.76 and 0.81 92. Remyelinated nerves naturally have a 
higher than expected G-ratio value due to reduced myelin sheath 
thickness. As well as thinner myelin sheaths, remyelinated nerves 
have shorter than average internodes. However, even with thin 
myelin sheaths and short internodes, remyelinated axons regain 
sufficiently fast conduction velocity to allow normal function in MS 
patients or in animal models of MS. As a result, the enhancement of 
remyelination has been identified as a key therapeutic strategy in 
MS and is the focus of much research. 
 
1.4  T lymphocytes 
 
1.4.1  T cell activation 
 
It is believed that the pathology of MS is produced by the 
activation of T helper cells, also known as T effector cells (Teffs), 
which have specificity for peptide sequences found in myelin 
proteins and launch autoimmune attacks against cells displaying 
these proteins. The activation of T cells requires simultaneous 
binding of a T cell receptor (TCR) by its cognate peptide and ligand 
binding of co-stimulatory surface proteins such as CD80. This co-
stimulation limits the activation of T cells to sites where 
inflammation, which causes antigen-presenting cells (APCs) to up-
regulate the surface expression of co-stimulatory molecules, 
coincides with presentation by major histocompatibility complex 
(MHC) molecules of antigens for which TCRs on the T cell are 
specific. In MS, host proteins are processed and displayed as 
peptides on APCs, and T cells may mount an immune response 
against cells and tissues containing these proteins – an autoimmune 
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response. It is well established that T cell clones that recognise 
epitopes of myelin proteins exist in MS patients 93, which supports 
this hypothesis. However, no specific host protein has been 
identified in all or even subsets of MS patients, and so the target of 
the autoimmune response remains unknown.  
 
1.4.2  T helper cells 
 
Two types of T helper cells have been implicated in the pathology 
of MS; these are T helper 1 (Th1) and the more recently 
characterised T helper 17 (Th17) cells 94,95. Th1 cells are 
predominantly pro-inflammatory T cells that are characterised by 
the expression and secretion of the pro-inflammatory cytokine 
IFN. Th17 cells, on the other hand, produce a different set of 
cytokines. Studies have shown that these cells, named for their 
distinctive production of the cytokine interleukin-17 (IL-17), co-
operate with Th1 cells in producing the CNS inflammation that 
leads to oligodendrocyte cell death and loss of myelin in MS. It was 
thought for a long time that IFN was the main driver of the CNS 
inflammation typical of MS. However, in the last twenty years 
several other cytokines have been identified that are necessary for 
induction of the murine MS model EAE. In experiments with mice 
in which the cytokines are genetically deleted singly it has been 
shown that interleukin-6 (IL-6) and interleukin-23 (IL-23) are 
required for EAE induction with an immunodominant MOG 
epitope. This is thought to be caused, in the case of IL-6-/- mice, by 
suboptimal activation of T cells and in IL-23-/- mice by poor 
differentiation of naïve T cells into Th17 cells 96-98. More recently a 
third cytokine has been added to the list of cytokines that are ‘non-
redundant’ in EAE. Two groups, reporting in Nature Immunology 
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recently, have shown that the encephalitogenicity of Th17 cells is 
dependent on the expression of GM-CSF, a cytokine secreted by the 
T cells themselves 99,100. In the proposed model, Th17 cells secrete 
GM-CSF that stimulates the secretion of IL-23 by dendritic cells 
(DCs), highly potent APCs. IL-23 in turn induces Th17 cells to 
produce more GM-CSF in a positive feedback mechanism that may 
explain the chronic nature of Th17-mediated immune reactions. 
This model also elegantly explains the importance of IL-23 in 
producing EAE. How GM-CSF produces EAE pathology is 
currently unclear although one proposed mechanism is through 
stimulation of a small number of CD11bhi–expressing myeloid cells 
100 or through macrophages 99. However, whilst these subtypes of T 
cell are highly damaging to the CNS there are other types of 
immune cell that work to limit their activation and thereby restrict 
the damage caused by these cells. 
 
 
1.4.3  Central tolerance: negative selection 
 
During normal thymic development of T lymphocytes, those cells 
that bind strongly to ‘self’ peptides (i.e. self-reactive) are deleted 
through a process called activation induced cell death (AICD). This 
mechanism, known as “Central Tolerance”, eliminates cells 
expressing self-reactive TCRs that arise naturally through VDJ 
recombination. In AICD, APCs in the thymus present self-peptides 
to developing T lymphocytes ectopically through the actions of the 
autoimmune regulator (Aire) transcription factor 101. Those cells 
that bind strongly to proteins displayed on APCs, such as 
macrophages and dendritic cells, undergo apoptosis. This essential 
mechanism prevents strongly self-reactive cells from leaving the 
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thymus and stimulating autoimmune attacks against body tissues. 
Humans and mice with a mutation causing dysfunction in the Aire 
protein suffer from severe autoimmune reactions as central 
tolerance fails 102,103. In humans this disease is known as 
autoimmune polyendocrinopathy candidiasis ectodermal 
dystrophy (APECED) 104 and is nearly always fatal. However, even 
in healthy people, some T cells expressing weakly self-reactive 
TCRs are allowed to develop normally without deletion. These cells 
with weakly self-reactive TCRs also express TCRs with specificities 
to a large number of non-self antigens and therefore effectively 
fight pathogenic infection. Removing them would compromise 
host immunity and be deleterious to the organism. So organisms 
that possess an adaptive immune system, such as humans and 
mice, have a circulating population of T-cells that also have the 
potential to launch an autoimmune attack on host tissues. This was 
shown in experiments that deleted a defined population of CD4+ 
cells in mice, producing autoimmune disease phenotypes 105.  
 
 
1.4.4 Regulatory T cells 
 
The evolved solution to this compromise is the presence of a 
population of self-regulating T cells known as Regulatory T cells 
(Treg) which suppress autoreactive T cells. These Treg also express 
host-specific TCRs and are more reactive to self-antigen than the 
weakly self-reactive Teffs 106,107. The difference is that the increased 
‘strength’ of self-reactivity exhibited by these cells in response to 
DC-expressed self-antigens in the thymus causes these cells to be 
sent down a different developmental pathway. Expression of the 
transcription factor forkhead box protein 3 (foxp3) is induced and 
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these cells develop a ‘suppressor’ phenotype. Foxp3 expression is 
induced by a number of transcription factors including the 
transcription factors Foxo1 and Foxo3 108 and it itself controls the 
transcription of several genes that are vital for Treg function, such 
as IRF4 and Blimp-1 109. Treg leave the thymus and circulate 
throughout the body binding to antigen-presenting cells (APCs) 
that express their cognate self-antigen bound to MHC proteins on 
their surface. On binding to these MHC-bound peptides, which are 
also bound by weakly self-reactive T cells, Treg become activated. 
This leads to increased secretion of the suppressor cytokines 
interleukin-10 (IL-10) and transforming growth factor β (TGFβ). It 
also leads to enhanced expression of certain surface proteins such 
as CTLA4, thought to act as a negative regulator of T cell activation 
through the trans-endocytosis of co-stimulatory molecules 
expressed on APCs 110. IL-10 has been shown to inhibit the 
activation of Th17 cells 111,112 that are associated with chronic 
autoimmune attacks whereas TGFβ is known to stimulate the 
development of new Treg, possibly increasing the effective local 
Treg population and it is also known to protect Treg from 
apoptosis during their development in the Thymus 113. In response 
to activation, Treg also secrete IL-2, a cytokine that is necessary for 
their development and proliferation. This may also lead to an 
increase in the local population of Treg, leading to more effective 
suppression of self-reactive T cell activation. This so-called 
‘Peripheral Tolerance’ acts to suppress the activation of T helper 
cells in the immediate vicinity and quell autoimmune attacks by 
self-reactive T cells. So vital is this regulation that mice and humans 
with deleterious mutations in the foxp3 transcription factor suffer 
from fatal autoimmunity similar to pathology associated with Aire 




1.4.5  Subtypes of Regulatory T cells 
 
Treg come in several different types and are part of a wider family 
of immune cells thought to have suppressor function. Of the three 
described sub-groups of Treg, two are found in vivo and the third 
can be produced from cells that are CD4+ foxp3- in vitro. The first 
group are known as ‘natural’ Treg (nTreg) since they arise in the 
thymus and cells of this subtype are produced by the thymus 
throughout life. These cells are the only known ‘dedicated’ foxp3-
expressing suppressor cells. These cells were first described in 1995 
as CD4+ CD25+ suppressor cells that were capable of rescuing 
‘nude’ mice reconstituted only with CD4+ CD25- cells from 
developing fatal autoimmune disease 105,114. It was not until more 
recently 115 that mutations of the transcription factor foxp3 were 
found to be the cause of immunodysregulation 
polyendocrinopathy enteropathy X-linked syndrome (IPEX), a 
severe and often fatal autoimmune disorder of humans 
characterised by multiple simultaneous autoimmune reactions 
against body tissues. This led to the discovery that foxp3 
expression is essential for the regulatory phenotype of Treg and 
transgenic mice with fluorescent markers driven by the foxp3 
promoter have made it much easier to obtain and identify Treg 
from these mice. Natural Treg typically secrete TGFβ and IL-10 and 
have a stable phenotype. The second type of Treg, sometimes 
referred to as ‘adaptive’ or ‘adapted’ Treg (aTreg) arise from CD4+ 
foxp3- T cells in vivo in response to environmental cues such as 
high concentrations of TGFβ. These cells have a transient 
suppressor phenotype and may be important in increasing the 
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frequency of Treg cells locally in response to signals from recruited 
nTreg, helping to control nascent autoimmune reactions. The third 
subtype of Treg is the ‘induced’ Treg (iTreg). These cells represent 
a therapeutically relevant class of Treg made in vitro from CD4+ 
foxp3- cells. This technique was first described in 2003 by Chen et 
al. 116 who showed that application of TGFβ and simultaneous 
stimulation of both the TCR and a separate surface receptor, CD28, 
could turn otherwise non-suppressing T cells into Treg in vitro 
through the induction of foxp3 expression in naïve T cells. Since 
then several groups have published refinements to this technique 
117 culminating with the discovery by Davidson et al. in 2007 that 
IL-2 is required for the efficient induction of iTreg cells 118. This 
discovery has brought the possibility of using Treg as an immune 
therapy against a number of autoimmune diseases a step closer. In 
the mammalian immune system, foxp3+ nTreg form less than 10% 
of the circulating CD4+ T cell population. Even if these cells could 
be isolated from patients without compromising Treg surveillance 
it would be too few cells to provide effective therapy. On the other 
hand iTreg can be made from the other 90% of the CD4+ cell 
population and therefore may provide enough cells for therapy. 
Recent breakthroughs in expanding Treg in the lab have brought 
this possibility a step closer 119-122. Several clinical trials are on-
going using injections of nTreg to protect against autoimmune 
diseases such as Graft Versus Host Disease (GVHD)119,123,124. Some 
of these trials use polyclonal Treg, meaning Treg that do not 
express TCRs with a specific affinity for the affected tissue. Some 
mouse studies have used Treg from transgenic mice that express a 
TCR specific for a particular protein epitope, such as the MBP-
specific Tg4 mouse 125 or the ovalbumin-specific OT-II mouse 126, on 
all T cells. These cells are described as monoclonal, as the whole 
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population has specificity for the protein of interest. In humans, 
monoclonal populations can be produced by selecting iTreg clones 
with a known specificity and encouraging these cells to proliferate, 
however this approach is expensive and therefore some groups 
have elected to use polyclonal cells with more general non-specific 
activation to the tissue of interest during autoimmune 
inflammation. The efficacy of monoclonal Treg in controlling CNS 
inflammation has been demonstrated in the mouse model EAE. In 
MS, Treg deficiency of numbers or function has been put forward 
by some as a possible contributory factor in the initiation of the 
disease 127,128. It has also been suggested that Treg from MS patients 
are not as efficient at migration 129 and, further, that it is only a 
subset of Treg which express IL-7 receptor alpha-chain which are 
functionally impaired and that the rest are normal 130. Treg have 
also been found within MS lesions seen in diagnostic tissue 
biopsies by some groups 1, although this is disputed by others 131. 
In the context of murine EAE, Treg are routinely found in the CNS 
at the peak of disease and express a particular cytokine, Leukaemia 
inhibitory factor (LIF), at levels that are almost seven-fold higher 
than similar cells in the periphery (unpublished data from the 
Anderton lab).  
 
 
1.5 Leukemia inhibitory factor (LIF) 
 
1.5.1 LIF signalling 
 
Structurally, LIF is 179 amino acids long and the murine form has 
78% homology with the human LIF protein 132. The tertiary 
structure of LIF is a bundle of four alpha helices in an ‘up-up-
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down-down’ configuration 133 (Fig.3(1)). The LIF protein is a 
member of the glycoprotein 130 (gp130) family of cytokines and, as 
such, acts through a heterodimeric LIF receptor (LIFR) made from 
the gp130 and LIF receptor  (LIFR) subunits 134. Ablation of the 
LIF gene is not lethal in mice and the only major phenotype is 
female infertility 135 that can be rescued with LIF injections 136. On 
the other hand, loss of LIFR signalling results in loss of motor 
neurons 137. Following LIF binding to LIFR (Fig.3(2)), the complex 
dimerises with gp130 and is phosphorylated by the Janus kinases 1 
and 2 (Jak1, Jak2) (Fig.3(3)), which in turn phosphorylate the 
transcription factor STAT3. Phosphorylation of STAT3 induces its 
dimerisation (Fig.3(4)) and the STAT3 dimer then translocates to 
the nucleus where it can either bind to DNA sequences containing 
a TT(N)5AA motif or form transcriptional complexes with other 
factors and bind to TT(N)6AA motifs 138 (Fig.3(5)). Inhibitors of LIF 
function include the STAT-induced suppressor of cytokine 
signalling 3 (SOCS3), which forms an intra-cellular negative 
feedback loop (Fig.3(6)), and LIF binding protein (LBP), which is 
found extracellularly 139. LBP is thought to act systematically and 










1.5.2  Function in CNS inflammation 
 
First characterised in 1988 as a factor that stimulates the 
differentiation of the leukemic M1 cell line 141, it was quickly shown 
that LIF is capable of inhibiting the differentiation of embryonic 
stem cells 142-144. In mice, LIF is a pleiotropic cytokine that acts on 
cells in many tissues, including the kidneys, the pituitary, the 
muscles and the bones 140. During CNS inflammation, LIF is 
protective against demyelination and axonal degeneration. Using 
the murine model of autoimmune CNS inflammation, EAE, it has 
been shown that administering antibodies against endogenous LIF 
leads to more severe disease, reduces the number of 
oligodendrocytes in the spinal column and also reduces global 
expression of MBP 145. This built on previous work showing that 
injections of recombinant LIF could decrease the severity of EAE in 
mice 146. This holds true even when LIF is overexpressed only in the 
CNS 147, supporting a CNS-intrinsic protective mechanism, rather 
than peripheral immune suppression. Knocking out the LIF gene in 
mice also lessens inflammation and reduces early neutrophil 
infiltration of the CNS 148. Further work suggests that this beneficial 
effect is independent of oligodendrocyte signalling as selectively 
knocking out gp130 expression in oligodendrocytes had no effect 
on the course of EAE 149. Such manipulations would, however, be 
expected to knock out the interleukin-6 (IL-6), oncostatin M (OSM) 
and cardiotrophin 1 (CT-1) signalling pathways as well 150, which 
makes this result hard to interpret. LIF is also secreted by myelin-
reactive T lymphocytes in the CNS of MS patients, and 
immunohistochemical staining shows that T cells in lesions also 




1.5.3  Function in oligodendrocytes 
 
LIF also exerts its effects on oligodendrocytes. Several studies have 
shown that LIF is effective in inducing oligodendrocyte survival 
and maturation in vitro 152,153. In co-cultures of neurons, astrocytes 
and oligodendrocytes, LIF is known to be secreted by astrocytes in 
response to neuronal activity. This secretion is enough to increase 
the number of mature MOG+ oligodendrocytes in these cultures, an 
effect that is blocked by anti-LIF antibodies 154.  In the cuprizone-
induced demyelination model in mice, LIF has also been shown to 
be beneficial. When treated with 50ug/kg of recombinant LIF, 
wildtype mice suffered less severe demyelination following 
cuprizone treatment. It was also found that LIF-/- mice suffer worse 
demyelination than wildtype mice 155, suggesting that LIF protects 
against demyelination. Furthermore, while administering 50ug/kg 
recombinant LIF during remyelination did not appear to have a 
beneficial effect, remyelination is inhibited in LIF-/- mice 155. 
Delivering LIF to the CNS via adenoviral delivery has also been 
shown to increase OPC and microglia proliferation and the rate of 
hippocampal remyelination following cuprizone treatment 156. It 
has also been shown that conditionally deleting SOCS3 in 
oligodendrocytes gave greater protection against cuprizone 
demyelination 157. Taken together with more recent work from the 
same group 149, this suggests that LIF promotes the survival, 
proliferation and maturation of oligodendrocytes, but also protects 
axons from inflammation independently of oligodendrocytes: both 
attractive goals for MS therapeutics.  
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Therefore the beneficial effects of LIF have been demonstrated in 
the context of global CNS inflammation and global CNS 
demyelination, but this has not yet been tested in focal 
demyelination, which I sought to do. 
 
 
1.6  LIF-containing nanoparticles 
 
1.6.1  Advantages of using nanoparticles 
 
Nanoparticles are tiny particles, often made from polymers of 
organic compounds, which are between 1 and 10,000 nanometres in 
diameter. They have several properties that are attractive to 
medical biologists. Firstly, they have a large surface area to volume 
ratio; a microgram of 1nm3 nanoparticles has the same surface area 
as 1kg of 1mm3 particles. They can also be manufactured in such a 
way that other compounds or molecules can be carried inside, and, 
by using particular compounds for their construction, they can also 
be made to biodegrade over a controllable number of days. The 
nanoparticles we have access to have all of these properties; they 
are roughly 100nm in diameter, they carry recombinant LIF protein 
within their structure, they are coated with avidin to provide 
binding sites for biotinylated antibodies and they biodegrade, 
when exposed to water, over seven days. The nanoparticles are 
made from a polymer, poly-lysine co-glycolic acid (PLGA), which 
is formed from two monomers: poly-lysine and glycolic acid. The 
relative amounts of these two molecules affect the rate at which 
these particles degrade 158. In experiments intended to establish the 
immunoreactivity of these nanoparticles in vivo, very little reaction 
is detected. After being injected into tissue, after only a few hours, 
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microglial activation is observed but no T lymphocyte infiltration is 
detected over the entire time that it takes for these nanoparticles to 
degrade naturally 159. Therefore, nanoparticles are attractive as 
carriers of therapeutic proteins. 
 
 
1.6.2 Delivery and Construction 
 
By binding avidin to palmitic acid molecules it has recently become 
possible to coat PLGA nanoparticles with avidin and thus make 
coating these nanoparticles with targeting antibodies 
straightforward 160. This has recently been demonstrated by 
targeting LIF-containing nanoparticles to T lymphocytes with a 
biotinylated anti-CD4 antibody 161. Targeting nanoparticles in this 
way has great utility, especially for intravenous injection. It is not 
clear whether nanoparticles of different sizes can cross the blood-
brain-barrier (BBB) following intravenous delivery. A recent paper 
which used nanoparticles to deliver anti-inflammatory drugs to the 
brain across the BBB is an important proof-of-principle 162, but it is 
not clear whether bigger nanoparticles of more than 100nm in 
diameter can do this. With a view to future use in patients with MS, 
it may be that the disruption of the BBB which occurs in the disease 
is sufficient to allow access to nanoparticles of this size. 
Nanoparticles containing dopamine have also been implanted 
directly into the rodent brain with some success, as the growth of 
dopaminergic neurons is boosted in such experiments 163,164. The 
PLGA-based nanoparticles used in my experiments are 
manufactured by initially mixing the murine LIF and PLGA 
together before immersing in oil. The oil immersion creates an 
emulsion of polymer and oil from which the nano-scale polymer 
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particles can be extracted and washed. Manufacturing these 
nanoparticles in this way ensures that LIF is encapsulated 
throughout the particle, ensuring that the protein is released over a 
longer time period. In fact these nanoparticles release LIF over 7 
days, although most of the release occurs over 48 hours 161. This 
construction method also creates a reasonably well-controlled size 
distribution of nanoparticle, with particles ranging between 50 and 
200nm 161.   
 
This project aimed to investigate the effect of Treg soluble 
cytokines, including LIF, on oligodendroglial cell biology, with the 
hypothesis that these cytokines may directly influence this biology 




















Chapter 2: General Tools and Methods 
 
Animal work was carried out in accordance with the University of 
Edinburgh regulations under Home Office rules, with local ethical 
committee consent. Experiments were carried out under the personal 
license 60/12865 and project licenses 60/3879 and 60/4116. 
 
2.1  Animals 
I used CD1 mice (Charles River) for all OPC isolations using Treg. 
For the isolation of CD4+ foxp3+ and CD4+ foxp3- cells a 
C57BL/6.Foxp3GFP mouse strain is used that expresses a fully 
functional fusion protein in which the eGFP gene is inserted into the 
first coding exon of the foxp3 gene 165. I also used Tg4 mice, which 
express a transgenic TCR protein that is specific for the acetylated 
N-terminal Ac1-9 epitope of MBP (Ac-ASQKRPSQR) 125. For LIF 
experiments, I used wildtype Sprague-Dawley rats as a source of 
OPCs. All animals were bred and maintained under veterinary 
supervision and in accordance with Home Office rules at a secure 
facility at the University of Edinburgh.  
 
 
2.2  Primary OPC culture  
The brains of P0-P2 rodent pups are harvested and the meninges are 
removed. The tissue is mechanically dissociated with scissors and 
then chemically dissociated with papain to obtain a suspension of 
cells in Dulbeccos modified Eagle medium (DMEM) (Gibco #41966). 
Cells are plated in T75 tissue culture flasks (Falcon #353110) in 
DMEM (Gibco #41966) supplemented with 10% b/v heat-
inactivated Horse Serum (HiHS) (Gibco #26050) and 1% b/v 
penicillin and streptomycin (p/s) (Gibco #15140). After incubation 
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for 7-10 days in 5% CO2 at 37°C, cultures are shaken and differential 
adhesion allows for the separation of OPCs from microglia and 
astrocytes as previously described 166. Isolated OPCs are plated at 
20,000 cells/well in 8-well chamber slides (Lab Tek #177445) in 
SATO medium 167,168 supplemented with 0.5% HiHS (Gibco #26050) 
and 10ng/ml fibroblast growth factor (FGF) (PeproTech #100-18B) 
and platelet-derived growth factor (PDGF) (PeproTech #100-13A) to 
maintain the OPCs in a proliferative, undifferentiated state. OPCs 
are cultured in these conditions for 24 hours before experimental 
factors are added. For (24hr) cell survival and differentiation 
experiments, conditioned media from other cell types are added at a 
1:1 ratio with 2X concentrated SATO medium in the absence of 
growth factors. Following the addition of experimental factors, 
OPCs are cultured for either 24 or 72 hours before fixation with 4% 
paraformaldehyde (PFA) (Sigma-Aldrich #P6148) and staining. In 
cell survival experiments taking place over 72hrs, OPCs are plated in 
1X SATO medium without growth factors until the 48-hour time 
point at which stage the experimental factors are then added as 
described previously. For proliferation experiments, experimental 
factors are added along with 5uM EdU (Invitrogen #C10340) and the 
cells fixed after 24hrs with 4% PFA (Sigma-Aldrich #P6148). 
 
 
2.3  OPC Immunocytology 
Cells are typically permeabilised using a 0.2% solution of Triton-
X100 (Sigma-Aldrich #T8787) in PBS and non-specific antibody 
binding is blocked using a 10% solution of HiHS (Gibco #26050) in 
PBS for 1 hour. The DeadEnd TUNEL Labelling kit (ProMega 
#G3250) and the Click-iT EdU Alexa Fluor 647 Imaging Kit 
(Invitrogen #C10340) are used for visualizing apoptosing cells and 
40 
EdU incorporation respectively, according to manufacturers 
instructions. Glial cell proteins are visualised using primary 
antibodies raised against MBP (Serotec, 1:300), NG2 (Milipore, 
1:200), O4 (Immunosolv, 1:1000), CD68 (Serotec, 1:200), GFAP 
(DakoCytomation, 1:500) and Olig2 (Millipore, 1:200). Cells are 
incubated with primary antibody diluted in blocking solution for 
either 1 hour at room temperature or overnight at 4°C. Cells are then 
incubated with the appropriate AlexaFluor secondary antibodies 
(Invitrogen) at room temperature for 1 hour and stained with 
Hoechst (1:2000) for 5 min. Coverslips are attached to all slides using 
Fluoromount G (Southern Biotech #0100-01).  
 
 
2.4  nTreg isolation and culture 
Brachial, axillary and inguinal lymph nodes as well as spleens are 
removed from Foxp3-GFP mice of at least 6 weeks of age. The tissue 
is mechanically dissociated using fine gauze and cells are suspended 
in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco 
#31870). Cells are then incubated with CD4 L3T4 Microbeads 
(Miltenyi #130-049-201) and the CD4+ population is separated using 
an AutoMACS Pro machine (Miltenyi). These cells are suspended in 
RPMI 1640 (Gibco #31870) supplemented with 20% heat-inactivated 
fetal calf serum (HiFCS) (Sigma #F7524) and sorted for GFP 
expression using a FACSAria II cell sorter (BD Biosciences). CD4+ 
GFP+ and CD4+ GFP- populations are recovered from this protocol. 
The GFP+ fraction is plated at 2x105 - 5x105 cells per well in 24-well 
plates (Costar #3524) coated with 2ug/ml of Anti-Mouse CD3e 
antibody (eBioscience #14-0031-86) and 2ug/ml Anti-Mouse CD28 
antibodies (eBioscience #14-0281-85) (αCD3/αCD28). The plating 
medium is either RPMI supplemented with 10% HiFCS (Sigma 
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#F7524), 2mM L-glutamine (Gibco # 25030-024), 100U/ml penicillin 
(Gibco # 15140-114), 100ugml-1 streptomycin (Gibco # 15140-114) 
and 50uM 2ME (Sigma # M7154) or AIM V medium (a serum-free 
medium) (Gibco #12055) supplemented with 2mM L-glutamine 
(Gibco # 25030-024), 100U/ml penicillin (Gibco # 15140-114) and 
100ugml-1 streptomycin (Gibco # 15140-114). Cells are incubated in 
5% CO2 at 37°C for 48 hours before the medium is removed and 
stored at -20°C between harvest and use. 
 
 
2.5 iTreg generation  
CD4+ GFP- cells recovered from the cell sorter are plated at 2x105-
5x105 cells per well on αCD3/αCD28-coated 24-well plates (Costar 
#3524) in RPMI 1640 (Gibco #31870) supplemented with 10% HiFCS 
(Sigma #F7524), 5ng/ml human recombinant TGFβ (RnD systems 
#240-B-002) and 100U/ml IL-2 as described previously 118. After 5 
days in 5% CO2 at 37°C cells are re-sorted using the FACSAria II cell 
sorter (BD Biosciences) for GFP induction. Cells expressing GFP are 
plated at 2x105 - 5x105 cells per well on αCD3/αCD28-coated 24-well 
plates (Costar #3524). The plating medium is either RPMI 
supplemented with 10% HiFCS (Sigma #F7524), 2mM L-glutamine 
(Gibco # 25030-024), 100U/ml penicillin (Gibco # 15140-114), 
100ugml-1 streptomycin (Gibco # 15140-114) and 50uM 2ME (Sigma 
# M7154) or AIM V medium (a serum-free medium) (Gibco #12055) 
supplemented with 2mM L-glutamine (Gibco # 25030-024), 100U/ml 
penicillin (Gibco # 15140-114) and 100ugml-1 streptomycin (Gibco # 
15140-114). Cells are incubated in 5% CO2 at 37°C for 48 hours 
before the medium is removed for analysis. 
 
2.6 Summary of Media used for experiments 
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Complete Medium: RPMI supplemented with 10% HiFCS (Sigma 
#F7524), 2mM L-glutamine (Gibco # 25030-024), 100U/ml penicillin 
(Gibco # 15140-114), 100ugml-1 streptomycin (Gibco # 15140-114) 
and 50uM 2-mercaptoethanol (Sigma # M7154). 
 
AIM V medium: (a serum-free medium) (Gibco #12055) 
supplemented with 2mM L-glutamine (Gibco # 25030-024), 
100U/ml penicillin (Gibco # 15140-114) and 100ugml-1 
streptomycin (Gibco # 15140-114). 
 
X-vivo: X vivo 15 chemically defined serum free haematopoetic cell 
medium (Lonza), 2mM L-glutamine (Gibco # 25030-024), 50uM 2-
mercaptoethanol (Sigma # M7154) 100U/ml penicillin (Gibco # 
15140-114), and 100ugml-1 streptomycin (Gibco # 15140-114). 
 
SATO medium (for OPCs): Dulbecco’s Modified Eagle’s Medium (DMEM) 
Sigma D-6546 containing 5000 U/ml Penicillin/Streptomycin solution, 
4mM L-Glutamine  Sigma G-6392, 16 g/ml Putrescine Sigma P-
5780, 400 ng/ml L-Thyroxine (T4) Sigma T-1775,  400 ng/ml Tri-
iodothyroxine (T3), Sigma T-6397,  60ng/ml Progesterone, Sigma P-
8783,  5 ng/ml Sodium Selenite, Sigma S-5261, 100 g/ml Bovine Serum 
Albumin fraction V, Sigma A-4919, 5 g/ml Insulin, Sigma I-1882 and 50 
g/ml Holo-Transferrin (human), Sigma T-0665. 
 
Slice culture medium: 50% MEM with Earle's salts, 25% Earle's Balanced 
Salt Solution, 25% heat inactivated horse serum (HIHS), glutamax-II 
supplement with penicillin–streptomycin, amphotericin B (all purchased 




2.7 Cytokine quantification  
The quantification of cytokines was performed using a combination 
of FlowCytomix simplex detection kits specific for: mouse IL-10 
(eBioscience #BMS8614/2FF), mouse GM-CSF (eBioscience 
#BMS8612FF), mouse IFN-gamma (eBioscience #BMS8606/2FF), 
mouse IL-17A (eBioscience #BMS86001FF), mouse IL-1alpha 
(eBioscience #BMS8611FF), mouse IL-2 (eBioscience #BMS8601FF), 
mouse TNF-alpha (eBioscience #BMS8607/2FF), mouse IL-23 
(eBioscience #BMS86017FF), mouse IL-4 (eBioscience #BMS8613FF) 
and mouse IL-22  (eBioscience #BMS86016FF). All kits were used 
according to the manufacturer’s instructions. A BD FACSCalibur 
Flow Cytometer (Becton Dickinson) was used for detection and the 
results were analysed with FloCytomix Pro2.4 software 
(eBioscience). 
 
2.8 Stereotactic Surgery 
Using anaesthetized 12 week old C57Bl/6 male mice, 2μl of 1% 
Lysophosphatidyl choline/Lysolecithin (LPC) was injected through a hole 
drilled in the skull at stereotactic coordinates 1.2mm posterior, 0.5mm 
lateral, 1.4mm deep to the bregma over 4 minutes using a 30 gauge needle 
attached to a Hamilton syringe, driven by a KD Scientific Nano pump, 
which was left in situ for 4 minutes to reduce backflow. Injection of T cells 
or nanoparticles were carried out not exceeding the same volume, using 
the same coordinates. At various time-points, mice were perfused with 4% 
PFA, and fixed brains were bisected coronally at the injection site.  
 
2.9 Tissue immunohistochemistry/fluorescence 
For staining of tissue sections, fixed tissue was cryoprotected in sucrose, 
frozen in OCT cryostat embedding medium (Tissue Tek, Agar Scientific) 
and 10μm sections were cut on a cryostat (Leica CM3050 S) and mounted 
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on superfrost slides (VWR International). Sections were washed in PBS 
and blocked in 10% normal horse serum in PBS containing 0.2% triton for 
1 hour in a wet chamber at room temperature (RT). They were then 
incubated with primary antibody at 4°C overnight. The next day, the 
sections were washed in PBS, incubated with appropriate fluorescently 
labelled secondary antibody (AlexaFluor, Invitrogen) in a wet chamber for 
2 hours at RT and washed in PBS again. Finally, the slides were mounted 
in fluoromount.  
 
To detect demyelination, Luxol fast blue (LFB) staining was performed 
using a standard protocol. In brief, slides were left in LFB solution 
overnight at 60C. Put slides into LFB solution. Lithium carbonate solution, 
and then 70% ethanol was used to differentiate the colours, and cresyl fast 
violet was used as a counter stain.  
 
2.10 Nanoparticles 
Nanoparticles were obtained from Dr Su Metcalfe at the University of 
Cambridge, and manufactured by the Tarek Fahmy Laboratory in the Yale 
School of Engineering and Applied Science. These were made from PGLA 
and either contained LIF, or not (as a negative control). These 
nanoparticles have avidin on their surface and were incubated with 
biotinylated NG2 antibody (species rabbit) (Millipore) to allow targeting 





Chapter 3: Results 
 
The first step in this project was to investigate the Treg and their secreted 
cytokines in vitro and validate the methods that we intended to use for 
their culture and analysis. In particular it was important to validate the 
novel set-up of our in vitro Treg cultures and analyse the effect that this 
might have on the Treg themselves.  
 
 
3.1 Regulatory T cell experiments 
 
3.1 Treg culture: survival and phenotypic stability 
 
Introduction 
I decided to begin by investigating the effects of Treg-secreted cytokines 
on OPCs. Rather than attempting to co-culture Treg and OPCs, I initially 
focused on generating Treg-conditioned media to add to OPC cultures. 
Previous studies into the effect of T lymphocyte cytokines on 
oligodendrocytes have generally used single recombinant cytokines, 
such as interleukin-2, to investigate this relationship. I pursued the 
strategy of testing the ‘whole’ Treg supernatant, including all of the 
secreted cytokines, in representative relative amounts. I felt that this 
approach would more faithfully replicate the in vivo situation, where the 
reality is that T lymphocytes do not secrete cytokines singly (see Table 1).  
The initial step in this strategy was to establish a technique for culturing 
Treg without high levels of serum, which would boost the viability of 
OPCs when Treg supernatants were added to OPC culture and skew the 
results. This involved using serum-free media for Treg culture and two 
different media were tried and compared to “complete” medium: AIM V 
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media (Gibco) and X-vivo media (Lonza). Due to the novel culture set-up 
required for generating Treg cytokines, the stability and survival of Treg 
of both types in culture was assessed. 
 
Method 
The foxp3-GFP mouse first used by Fontenot et al. (2005) 165 was used as 
a source of both natural and induced T regulatory cells. Harvest and 
generation of Treg (see methods) involves the removal of spleen and 
lymph nodes from 6-10 week-old mice before the tissue is processed to 
remove blood cells and separate immune cells. Those T lymphocytes that 
express CD4 can then be separated using magnetic beads coated with 
anti-CD4 antibodies using the magnetic-activated cell sorting (MACS) 
system. This population of CD4+ T cells can finally be sorted, using 
fluorescence-activated cell sorting (FACS), for those expressing GFP 
(natural Treg) and for the binding of fluorescent antibodies to CD62L 
and CD25 (naïve T cells). Plating nTreg for 48h in varying media and in 
the presence of TCR and co-stimulatory antibodies (anti-CD3, anti-CD28) 
gives nTreg supernatant. Naïve T cells, plated in anti-CD3 and anti-CD28 
coated wells with media supplemented with IL-2 (200U/mL) and TGFb 
(5ug/mL) for 5 days, gain expression of foxp3 and can therefore be 
sorted using FACS for GFP expression. A further 48h of cell culture gives 
induced Treg (iTreg) supernatant. Wherever possible, the use of the 
cytokine IL-2 was avoided as IL-2 has been reported to influence the 
proliferation and maturation 3. I compared standard T cell culture 








To obtain nTreg, the foxp3-GFP mouse where all cells that express foxp3 
fluoresce green, and by FACS for GFP, I could obtain 100% GFP+ 
expression in plated cells (nTreg). After 48 hours in culture without IL-2, 
which is important for nTreg survival, the cell medium was removed and 
the cells analysed using a combination of FACS, to look for both their 
GFP expression and survival, and Trypan Blue (TB) staining, for the 
integrity of the plasma membrane. In the analysed cells, the proportion of 
nTreg expressing GFP typically dropped to 89.8% of total cells in 
complete medium and 99.93% and 90.1% in AIM V and X-vivo medium 
respectively (Fig. 4A), suggesting reasonable stability of the cell 
phenotype. However, cell survival was quite low as shown both by 
staining with TB and by the proportion of events in the ‘live gate’ of 
FACS analysis. When analysed by flow cytometry, the survival rates were 
15.6% of total detected events in complete medium, 13.7% in AIM V and 
16.35% in X-vivo medium (Fig. 4B). This trend was mirrored closely when 
analysed through staining with TB, counting approximately 400 cells per 
group. In complete medium 27.83% of cells survived, in AIM V the rate 
was 1.5% and with X-vivo medium, 19.32% (Fig. 4C). These very low 
survival rates can partially explain the very high rates of GFP expression 
observed as only a small proportion of very healthy cells, with robust 
GFP expression, remained after 48h without IL-2.  
 
iTreg 
With iTreg, a slightly different pattern was observed. Again, the GFP+ 
iTreg were sorted using FACS and only GFP+ cells were plated out, 
giving a culture with 100% GFP positivity. When GFP expression after 
culture for 48h in the absence of IL-2 is analysed, the frequencies of GFP+ 
cells are generally lower: 43.03% in complete medium, 80.92% in AIM V 
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medium (56.7% when supplemented with 50uM of 2-mercaptoethanol (2-
ME)), and 51.12% when the cells were cultured in X-vivo medium.  
As a preliminary experiment testing whether Treg have a stable 
phenotype in culture media optimised for oligodendrocyte culture, Treg 
were plated for 48h in the media from two such cultures. The eventual 
aim of this experiment was to see if co-culturing oligodendrocytes, either 
in vitro or ex vivo, with Treg was viable. Tests to analyse iTreg survival in 
the two oligodendrocyte medium solutions, Slice culture medium and 
SATO medium, resulted in GFP-positivity rates of 44.85% and 16.85% 
respectively (Fig.5A). Thus, stability of iTregs under all of these culture 
conditions was much lower than in previously tested culture media 
(complete media). 
 
Survival of these cells was analysed in the same way as for the nTreg 
cultures, by FACS sorting and numbers of cells in the live gate and by 
trypan blue staining and microscopy. When using flow cytometry as a 
measure of cell survival, 32.88% of cells survived in complete medium, 
only 7.5% in AIM V medium, rising to 75.15% in AIM V medium 
supplemented with 50uM 2-ME and 64.7% in cells cultured in X-vivo 
medium. For slice culture medium and SATO medium only a very few 
cells survived: 0.30% and 24.4% respectively (Fig. 5B). In close agreement 
with this, the percentage of iTreg that were negative for TB staining was 
49%, 6.73%, 82.34% and 71.29% respectively - clearly showing that iTreg 
survive well in AIM V supplemented with 2-ME and X-vivo medium 
(Fig. 5C). The frequency of cells surviving, as measured by staining for TB 
from slice culture medium and SATO medium was 1.17% and 28.85% 
respectively, which was relatively poor (Fig. 6). Thus, iTreg seem to 
survive better than nTreg under these culture conditions, but they are 




There is a loss of survival of Treg cultured in media without serum, 
which is more marked with nTreg than iTreg. However, the stability of 
Treg in culture in media without serum after 48 hours, as determined by 
their foxp3-driven GFP expression is also variable, but most stable in the 
AIM V medium with additional 2-ME. 
Overall, the percentage of live cells expressing GFP was higher in cell 
populations suffering from poor survival. This is probably because only 
the ‘healthiest’ cells, which are assumed to have the strongest protein 
expression, including that of GFP, survive in these conditions. In essence, 
while 100% of a small surviving cell population might be GFP+, possibly 
only 50% of cells in a much larger surviving population may express GFP, 
meaning the absolute number of GFP+ cells is far higher.  
 
I used these Treg supernatants to treat oligodendrocytes, as I expected 
that activated Treg would have secreted appreciable amounts of 
cytokines before losing GFP expression or cell death. This was preferred 
over the addition of relatively large amounts of IL-2 to the culture 
medium since this cytokine is known to boost oligodendrocyte 
proliferation 3.  
 
 
3.2 In vitro Treg culture supernatants contain cytokines 
 
Introduction 
Having established a culture system for obtaining nTreg and iTreg 
supernatants in a variety of media, I analysed the supernatants in order to 
establish the types and amounts of cytokines that they contained. Since 
the Treg were cultured in wells coated with CD3- and CD28-stimulating 
antibodies, they were assumed to be in an activated state and therefore 
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likely to be secreting cytokines involved in their suppressive function, 
such as IL-10 and TGFb. We expected the Treg to be secreting these and 
other cytokines plus small amounts of growth factors that have been 
reported previously (see table 1). Establishing every cytokine that the 
Treg secreted was not my main objective, as it would be too technically 
demanding and time-consuming, rather my aim was to ask whether some 
of the cytokines that have previously been studied, such as IFNg and 
TNFa, were present in our supernatants. This would allow us to try and 
predict the effect that these supernatants would have on 
oligodendrocytes based on previous reports (see table 1). 
 
Method 
As there was no feasible way to detect all of the proteins secreted by Treg 
within the scope of this project, I instead looked for likely candidates 
using a customised ‘flowcytomix’ assay. This assay consists of a mixture 
of different fluorescent bead-bound cytokine-specific antibodies, which 
bind to the cytokine of interest and can be distinguished by the size of the 
bead and its fluorescent label using FACS. This provides a simultaneous 
analysis of ten or more cytokines from the same sample. I customised the 
kit that I used to include 10 cytokines of particular interest and tested for 
TGFb separately. The cytokines were selected following a literature 
search for cytokines that Treg were likely to secrete (as shown in table 1). 
TGFb must be assayed separately because it is secreted in an inactive 
form that is ‘activated’ under acidic conditions. Therefore in order to 
detect TGFb using an antibody against active TGFb the Treg supernatant 
must be acidified with hydrochloric acid, done using an eBioscience 




Treg were extracted and cultured as previously described (see section 
3.1). The supernatants from nTreg and iTreg cultured for 48 hours were 
removed and analysed for their cytokine content.  
When cultured for 48h in complete medium, nTreg secreted few, if any, 
cytokines from my array, which included the archetypal Treg-secreted 
cytokine IL-10. The only cytokine detected consistently was IL-1a, and the 
level of this cytokine was close to the limit of sensitivity of the kit used 
and therefore may represent a false positive result (Fig. 7).  
On the other hand, iTreg secreted a number of cytokines and in great 
amounts. Interferon gamma (IFN) was particularly highly expressed by 
these cells with almost 26ng/mL detected. The cytokines GM-CSF 
(0.153ng/mL), TNF (0.127ng/mL) and IL-4 (0.146ng/mL) were also 
found in relatively large amounts in iTreg supernatants (Fig. 7). These 
results indicate that nTreg were not able to secrete cytokines well in 
culture, or that they express and secrete proteins that we did not test for. 
The absence of IL-10 is surprising, however it may be that poor survival 
of nTreg in these cultures reduced the level of secreted IL-10 to below the 
detection limit of these tests.   
 
Testing for TGFb, relies on the acidification of samples, and therefore 
TGFb was assayed separately from other cytokines. Tests on Treg 
supernatants revealed a concentration of 671.60 pg/mL in iTreg 
supernatants, and 539.57 pg/mL in nTreg supernatants containing 10% 
fetal calf serum by volume (Fig. 8A,B). No TGFb was found in 
supernatants from cultures grown in serum-free media. Tests of the fetal 
calf serum used to supplement the media showed that the observed TGFb 
concentration could be entirely be accounted for by the serum content of 
the supernatants, as pure fetal calf serum contained a concentration of 
5405.07 pg/mL TGFb (Fig. 8C). This constrains the levels of TGFb 
actually secreted by these cells to very low levels of free TGFb. A possible 
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explanation is that the TGFb produced by these cells is in the form of 
membrane-bound TGFb (mTGFB) rather than secreted, which would then 
require direct contact with oligodendrocytes or cleavage and release to 
have any biological effect in vivo. 
 
Summary 
These results therefore show that iTreg secrete a range of cytokines (IFNg, 
TNFa, GM-CSF and IL-4) but my cultured nTreg did not convincingly 
produce any of the cytokines I chose to measure, including IL-10. This is 
unexpected and may be related to the poor survival or lack of continued 
activation of nTreg in my culture conditions. Other cytokines or growth 
factors may also have been present, and it would have been interesting to 
measure these by QPCR.  
 
I next aimed to determine whether these secreted factors had any effect 
on OPC biology. 
 
 
3.3 Treg supernatants have no effect on OPC proliferation in vitro 
 
Introduction 
Having set up Treg cultures and harvested media from these cultures that 
contained a number of cytokines proven to affect oligodendrocytes, I 
began to test these supernatants on OPCs in culture. Our rationale was to 
find out if the combination of these different Treg-secreted cytokines 
would affect oligodendroglial cell behaviour particularly OPC 
proliferation, viability and differentiation which impact on the efficiency 
of remyelination in vivo. In response to CNS inflammation, proliferation 
is desirable to maximise the number of OPCs available for repair, 
increased viability should preserve the local population of OPCs available 
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for repair and enhanced differentiation into myelinating 
oligodendrocytes should provide the largest possible population of 
mature oligodendrocytes capable of remyelination. I began by testing the 
effect of Treg-conditioned media on proliferation, a reliable and easily 
analysed cell behaviour that is desirable for tissue repair.  
 
Method 
OPCs were obtained by the shake-off method from P0-P2 mice and plated 
on poly-D-lysine-coated 8-well chamber slides, with 20,000 cells per well. 
OPCs were cultured in SATO medium for 24h with PDGF and FGF at 
10ng/mL b/v. After 24h, the medium was changed to 2X concentrated 
SATO medium diluted to 1X concentration with Treg supernatant and 
containing 5mM 5-ethynyl-2’-deoxyuridine (EdU), so that Treg 
supernatant accounted for 50% of the volume, but the growth factors and 
supplements in SATO were at the normal concentration. After 24h these 
cells were fixed and EdU incorporation in OPCs exposed to Treg 
supernatant was compared with incorporation in those that had been 
treated with vehicle T cell medium only.  
 
Results 
As mouse OPC cultures are less pure than rat cultures using the shake-off 
technique, I first measured the proportion of total cells that expressed 
Olig2, a classic oligodendrocyte marker, which was on average ~60%. 
Therefore, I needed to co-stain cells with a proliferation marker and an 
oligodendroglial marker to ensure that I was measuring the response of 
OPCs in the cultures to the Treg supernatants, and not other cells. 
Initially I used BrdU to identify proliferating oligodendrocytes but this 
marker did not prove to be reliable enough as surface antigens required 
for correctly identifying OPCs were destroyed by the required antigen 
retrieval step for BrdU immunostaining. However, the use of EdU 
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incorporation into dividing cells over time and an antibody to 
proliferating cell nuclear antigen (PCNA), labelling cells actively dividing 
at one time-point ultimately proved to be more consistent.  5mM EdU 
was added to OPC cultures 21 hours after the addition of Treg 
supernatants, 3 hours prior to fixation. At the same time, fixed cultures of 
OPCs were also immunostained for PCNA. 
 In OPCs treated with supernatants from nTreg, the level of EdU 
incorporation of oligodendroglial cells was almost identical to control 
levels (Fig. 9). This was the case regardless of whether nTreg had been 
cultured in complete medium (Fig. 9A), AIM V medium (Fig. 9B) or X-
vivo medium (Fig. 9C). PCNA staining followed a similar pattern and did 
not vary significantly from control levels with any treatment. 
 
The same was true of OPCs treated with supernatants from iTreg 
cultures. Again, in these cultures approximately 60% of cells expressed 
the oligodendroglial marker Olig2. There was no difference in EdU 
incorporation with OPCs treated with iTreg supernatant using complete 
medium (Fig. 10A), AIM V medium (Fig. 10B) or X-vivo medium (Fig. 
10C). PCNA staining followed a similar pattern and did not vary 
significantly from control levels. 
 
Summary 
Therefore, neither nTreg nor iTreg supernatants had any significant effect 
on oligodendrocyte proliferation. The OPC proliferation rate did vary 
depending on the type of culture media added to the OPCs  - EdU 
incorporation when X-vivo medium was added was lower generally, at 
approximately 40% of cells compared to approximately 60% of cells with 
the other culture conditions (Fig. 9C, 10C). However, there was no 
difference between proliferation rates in OPCs treated with Treg 
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supernatants compared to those that had not been conditioned by Treg 
using any type of media. 
 
 
3.4 Treg supernatants have no effect on OPC differentiation in vitro 
 
Introduction  
The second cellular behaviour that I analysed in the presence of Treg-
secreted cytokines was the differentiation of oligodendrocytes. Within the 
scope of these experiments ‘differentiation’ was defined as changes in 
OPC biology which led to surface expression of NG2 followed by O4 and 
then, most importantly, MBP. Boosting the number of MBP-expressing 
oligodendrocytes within and around demyelinated lesions may make 
successful remyelination more likely. Some reports describe a 
‘differentiation block’ amongst OPCs in lesions where many OPCs are 
found but very few differentiated oligodendrocytes 79. This makes finding 
ways of boosting OPC differentiation all the more important.  
 
Method 
OPCs were obtained via the shake-off method and plated at a density of 
20,000 cells per well into 8-well chamber slides containing SATO-medium 
supplemented with 10ng/mL PDGF and FGF. After 24h the medium was 
removed and 2X SATO medium diluted to 1X SATO with Treg 
supernatant was added to some wells and 2X SATO medium diluted with 
‘vehicle’ medium added to others as a control. 24 and 72 hours later, the 
cells were fixed and the cells immunostained for MBP and Olig2. Cells 
were imaged using a confocal microscope, blind-counted and the number 





Initially three different oligodendrocyte markers were used to try and 
determine the extent of differentiation of OPCs. The OPC-specific 
proteins chondroitin sulphate proteoglycan (NG2), sulphatide (O4) and 
myelin basic protein (MBP) were used to identify OPCs in early, 
intermediate and mature stages of differentiation (Fig. 2). Unfortunately 
this technique relied on all markers having optimal immunostaining and 
this was not always the case. This method had been developed by a 
colleague in the MS centre using rat OPCs, but was less reliable in mouse 
OPCs, possibly as the O4 antibody used was of mouse origin. Therefore, I 
elected to use only the very reliable MBP immunostaining to quantify 
OPC maturation. This is arguably more relevant to the assessment of the 
remyelinating potential of these cells, as studies of human lesions show 
that some OPCs appear to suffer so-called ‘differentiation block’ and fail 
to mature into MBP-positive oligodendrocytes 79.  
 
When supernatants from nTreg were added to OPCs as above, there was 
no significant increase in the number of MBP-positive cells regardless of 
whether the Treg were originally cultured in complete medium (Fig.11A), 
AIM V medium (Fig.11B) or X-vivo medium (Fig. 11C). In all cases the 
percentage of all cells that expressed MBP was between 0 and 5%. As this 
appeared to be rather variable, I investigated whether this varied with the 
litter of mice used. I plotted the amount of MBP expression of OPCs 
according to which litter of mice that they came from, rather than the 
treatment they received, and there appeared to be less variation using 
OPCs within litters, and bigger differences in the OPC maturation 
between litters than between treatment groups (Fig. 11D). This suggests 
that the precise age of the pups used to extract OPCs, the environment of 
the mother or genetic factors may have more of an effect on MBP 
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expression in these cells than the effect of Treg supernatants. This was 
true even using 2 different litters of mice on the same day.  
 
With iTreg supernatants, a similar set of results was observed. Again, 
between 0 and 4% of total cells in these OPC-enriched cultures expressed 
MBP and this did not vary significantly from control cultures in any of 
the three types of media; complete medium (Fig. 12A), AIM V 
supplemented with 2-ME (Fig. 12B) or X-vivo medium (Fig. 12C). 
Similarly to nTreg, there seemed to be more of a correlation between the 
litters that OPCs had been harvested from and MBP expression rather 
than between MBP expression and supernatant type (Fig. 12D).  
 
Summary 
Therefore, Treg supernatants have no effect on OPC maturation in vitro.  
 
The number of MBP positive cells in these cultures generally was low in 
all of these experiments, which makes interpretation of differences 
difficult. It is apparent that mouse OPCs mature slower than rat OPCs in 
culture, and therefore it may be worth repeating this at a later stage in 
culture, when more cells have matured in the control group. 
 
 
3.5 Treg supernatants have no effect on OPC apoptosis in vitro 
 
Introduction 
During CNS demyelination, regardless of whether it is initiated by CNS 
inflammation or demyelinating substances such as cuprizone or LPC, 
involves the death of oligodendrocytes. Protecting oligoendroglial cells 
from apoptosis by providing trophic factors that boost their heath, rather 
than by blocking apoptotic signalling, may be of therapeutic benefit. I 
58 
hypothesised that protecting pre-existing OPCs from cell death in the 
environs of a demyelinating lesion would boost the population of OPCs 
available for repair and therefore be beneficial to subsequent 
remyelination. To analyse apoptosis in vitro in response to Treg-secreted 
cytokines I added Treg supernatants to OPCs and quantified the number 
of OPCs undergoing apoptosis as measured by terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). 
 
Method 
OPCs obtained using the shake-off method were plated at 20,000 cells 
per well in 8-well chamber slides. After being exposed to the growth 
factors FGF and PDGF at 10ng/mL concentration the media was 
withdrawn and replaced with either 2X SATO media diluted to 1X with 
various Treg supernatants or 2X SATO medium diluted to 1X with 
vehicle medium. OPCs were fixed at 24 or 72h and apoptotic cells were 
visualised using a TUNEL assay. OPCs were also immunostained with 
anti-Olig2 antibodies to establish the number of apoptotic OPCs as a 




To analyse the effect of Treg-conditioned media on OPC cell survival in 
vitro, OPCs were harvested from the cortices of P0-P2 mouse pups and 
cultured for 24h, at which point Treg supernatants were added. These 
cultures were maintained for either a further 24 or 72h before being fixed 
and apoptotic cells were visualised with terminal deoxynucleotidyl 
transferase dUTP nick-end labelling (TUNEL). These time-points were 
chosen to look for the effect of Treg supernatant on immature OPC and 
more mature oligodendroglial cells. By co-staining for Olig2 it was 
possible to assess the number of oligodendroglial cells undergoing 
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apoptosis. Due to the level of double-labelling being very low the ratio of 
the total number of apoptotic bodies to cell nuclei was also measured to 
give an ‘apoptotic index’. On both of these measures there was no 
significant difference between control and Treg-conditioned media (Fig 
7).  
 
As with previous cultures, the percentage of total cells in these cultures 
that expressed Olig2 was between 60 and 70% and this did not vary 
between treatments. At 24h after the addition of nTreg supernatants from 
nTreg grown in complete medium, there was no difference in apoptosis 
between both control and nTreg-treated media (Fig. 13A). At 72h, there 
was more apoptosis, but again with no significant difference between 
control and conditioned media (Fig. 13B).  When apoptosis was measured 
as a percentage of Olig2+ cells that were also TUNEL+ the proportion of 
cells undergoing cell death was very low, not even reaching more than 
1% in either conditioned media or control at 24 (Fig. 13C) and 72h (Fig. 
13D). The suggestion from these experiments is that the components of 
nTreg-conditioned complete medium have no effect on OPC cell survival. 
These experiments were repeated with nTreg-conditioned X-vivo 
medium instead of complete medium, as a serum-free alternative to the 
complete medium assayed previously. Measurements of ‘apoptotic index’ 
and of the co-staining of Olig2 and TUNEL showed an apparent trend 
towards lower rates of apoptosis in the Treg-conditioned media (Fig. 14), 
but this is not statistically significant.  
 
At the same time the effect of similar media conditioned by iTreg instead 
of nTreg was assayed. Using the same culture set-up and analysis, the 
effect of iTreg-conditioned X-vivo media on OPC cell survival was 
measured. When the apoptotic index was calculated at 24h (Fig. 15A) and 
at 72h (Fig. 15B) there was no significant change from the control values, 
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though again it was rather variable. When assessing death as a 
percentage of the total Olig2+ population that also stain with TUNEL 
there was, again, no significant difference between conditions at 24 (Fig. 
15C) or 72h (Fig. 15D), but with much variability.   
 
Summary 
Therefore, Treg supernatants have no effect on oligodendroglial survival 
in vitro. The variability that I have seen in these experiments may be due 
to the very low level of apoptosis in these cultures, and this could be 
repeated using a deprivation medium (lacking serum and growth factors) 
to stimulate a higher death rate and to determine whether the Treg 
supernatant addition can rescue this. Alternatively, this variability may 
be related to the variation in cytokine amounts released by Treg in 
different cultures on different days, in spite of having done the 
experiment in the same way each time. 
 
Summary of Results so far 
I found no difference in OPC proliferation, maturation or death by 
applying Treg supernatants to OPC cultures. There were some problems 
with these experiments, in that the survival of Treg in culture, when the 
supernatants were being formed, was sometimes low, and the stability of 
these cells in terms of remaining Treg (at least by Foxp3-GFP expression) 
was variable and certainly not 100%. This may have influenced the type 
or amount of cytokines produced into the supernatants at each extraction. 
This may account for some of the variability seen in each of these 
experiments, making it difficult to discern any effect. Secondarily, mouse 
OPCs are much harder to extract from brain successfully, mature slower 
and may be more variable between extractions than rat OPCs (the 
standard used in the MS centre), compounding matters. To circumvent 
some of the problems of Treg culture, stability and variability of 
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supernatants, I decided to perform pilot studies of demyelinated brain 
lesions in vivo, to determine whether it was feasible to add Treg directly 
to these lesions and determine any effect on remyelination in a more 
representative cellular environment. 
 
3.6 Chemically-demyelinated lesions contain no T lymphocytes 
 
Introduction 
My hypothesis was that Treg, injected into a chemically demyelinated 
lesion, would enhance the spontaneous remyelination of such a lesion. 
My first aim was to characterise the immune cell types already found in 
demyelinated lesions in order to better understand how the 
microenvironment would affect the behaviour of injected Treg. I looked 
for the presence of T lymphocytes and antigen presenting cells, as it 
would be desirable for Treg to receive endogenous TCR and co-receptor 
stimulation through interactions with MHC class II molecules to increase 
their cytokine output.  
 
Method 
Stereotactic apparatus was used to inject 2uL of LPC into the corpus 
callosum of 10-week old mice under anaesthetic. Mice were then perfused 
intracardially with 4% paraformaldehyde and the brains post-fixed in 
15% sucrose solution for 24h followed by 30% sucrose for a further 24h. 
Tissue was then embedded in OCT before being sectioned using a 
cryostat and stained using luxol fast blue to visualise lesioned areas. 
Adjacent sections containing lesions were then immunostained for 




Injecting the chemical lysophosphatidylcholine (LPC) into the corpus 
callosum leads focal demyelination. I assessed whether T lymphocytes, 
and especially Treg, infiltrate the site of demyelinated lesions in this 
model. Brain tissue taken from mice that received LPC injections 3- and 4-
days previously was immunostained using the T cell marker CD4 and the 
Treg marker foxp3. It was also analysed for the presence of microglia 
(Fig. 16A) and astrocytes (Fig. 16B) to test for innate immune system 
activation. Splenic tissue was used as a positive control for antibody 
staining, and contained both CD4-positive (Fig. 16E) and foxp3-positive T 
cells (Fig. 16F), yet no such cells were found in this brain tissue (Fig. 
16C,D). As one article had suggested a brief influx of T cells into similar 
lesions in the spinal cord at 8 hours after lesion 169, I assessed tissue 8 
hours and 24 hours after LPC injection, but again no T cells were seen. 
This led me to conclude that T cells do not infiltrate corpus callosum 
lesions after LPC injection. The difference in findings between LPC 
injection in the spinal cord and the corpus callosum may be related to the 
fact that the spinal cord is much smaller and lesioning it may produce 
enough inflammation, relative to volume, to allow entry to T cells 
through more breakdown of the blood brain barrier locally.  
Therefore, in our model, the adaptive immune response is not activated, 
perhaps making it ideal to see whether factors produced by Treg have an 
effect directly on remyelination with no chance of an effect on T cells in 
the lesion, as there are not any present. Hence, it is a clean and simple 
system to answer the specific question of whether factors from Treg 
directly influence OPCs and remyelination. 
 




Next, I analysed how well T lymphocytes survive injection into mouse 
brain and whether they persist in vivo. This was to help determine how 
many Treg should be injected and whether this would need to be 
repeated and how often.  
 
Method 
CD45.1 mice were lesioned using stereotactic apparatus to inject 2uL of 
LPC into the corpus callosum. For reasons of numbers, I used naïve T 
cells which were obtained from CD45.2 mice using the FACS technique to 
sort out CD4+ CD62Lhi CD25- cells. These were injected into CD45.1 
mice, with a focal demyelinated lesion, to allow me to use specific 
antibodies to ensure that any Tcells found in the lesion could be identified 
as host (CD45.1) or transplanted (CD45.2). 10,000 naïve T cells were 
injected into the lesion either 24h following LPC injection. This number 
was chosen as it has been calculated in the Anderton lab that there are 
approximately 10,000 Treg present in brains of mice recovering from 
EAE, and it is known that this number is sufficient for that recovery (data 
unpublished). Mice were perfused intracardially with 4% 
paraformaldehyde 24, 48 or 72h following T cell injection and were post-
fixed with 15% sucrose solution for 24h followed by 30% sucrose for a 
further 24h. Tissue was embedded in OCT and sections were obtained 
using a cryostat. Cryostat sections were stained with luxol fast blue to 
indicate the location of demyelinated lesions and sections containing 
lesions were immunostained for the presence of immune cells with 
antibodies against CD4 (to visualise T cells) and CD45.2 (to visualise 




After injection of 10,000 naïve T cells from CD45.2 mice into the lesion site 
of CD45.1 mice 24h or 5 days after LPC treatment, no T cells were seen in 
or around the lesions by immunofluorescence staining. 
One hypothesis for this absence of cells is that the injections of T cells in 
this initial experiment may have been too soon after the LPC injection; 
therefore enough toxin may have still been present to damage the T cells. 
Thus, we repeated the experiment 5 days post-LPC injection to inject T 
cells and checked for their presence after 24 hrs. However, again, no T 
cells were identified.  
This absence of local T cells may be because the cells used were naïve,  
not activated before injection, and therefore would not be primed to 
respond to the demyelinated lesion environment. They may have been 
unable to respond to the inflammatory cues of the demyelinated lesion, 
and simply migrated back into the bloodstream. The absence of 
transplanted T cells in the lesion discouraged me from attempting to 
inject Treg into LPC-induced demyelinated lesions and suggests that in 
these lesions, T cells do not receive the correct molecular cues necessary 
to persist locally in previously demyelinated tissue. 
 
At this stage of the project, I decided to switch to a more candidate-based 
approach, selecting a candidate known to be released by Treg and which 
may affect OPC behaviour and remyelination. Work done in the Anderton 
lab to determine whether the cytokine profile of Treg isolated from the 
CNS and from the peripheral circulation are similar or different revealed 
that CNS Treg highly express the cytokine LIF at a level of 7 x higher than 
peripheral blood Treg. For this reason, and as LIF has already been shown 
to have effects on OPC function, I decided to focus on this cytokine. As 
before, I examined the effect of LIF on OPC proliferation, maturation and 
survival in culture, as these are important steps that OPCs must achieve 
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for successful remyelination and also investigated a novel nanoparticle 
delivery method for getting it to OPCs in lesion sites. 
 
3.2  Leukaemia inhibitory factor (LIF) 
 
3.2.1 The T cell secreted cytokine leukaemia inhibitory factor (LIF) does not 
significantly increase OPC proliferation 
 
Introduction 
As LIF is highly expressed by CNS Treg (unpublished data) and has well 
documented beneficial effects on both CNS inflammation 145-148 and 
oligodendroglial cell behaviour 154-156,170 , I decided to test its efficacy in 
vitro in the same way that I tested Treg supernatants. I first tested 
whether OPCs grown in media containing recombinant LIF proliferated 
more than controls.  
 
Method 
As an initial experiment to test the effect of LIF on OPCs in vitro, OPCs 
were harvested from P0-P2 mouse pups using the shake-off method as 
before and cultured for 24h in SATO medium supplemented with FGF 
and PDGF at 10ng/mL concentration. This was then removed and 
replaced with SATO just containing murine LIF (mLIF). mLIF produced 
from COS7 cells (obtained from the centre cell culture facility) was tested 
at a range of concentrations from 50, 100, 200, 500 or 2000U/mL to attain 
a dose-response profile for its effect on OPC proliferation. As a positive 
control for OPC proliferation, the proliferative factor PDGF was added at 
10mg/ml. As a negative control, cells were incubated just in SATO 
medium. After 21h the medium was supplemented with 5mM EdU and 
fixed using 4% paraformaldehyde 3h later. Fixed cells were assayed for 
EdU incorporation and immunostained for Olig2 to indicate the 
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percentage of OPCs that incorporated EdU. Cells were imaged using a 
confocal microscope and blind counted. 
 
Results 
In these cultures, as before, the proportion of cells which were 
oligodendroglial (expressing Olig2) was constant at around 60% of total 
cells and did not vary between conditions. Adding 50, 100, 200, 500 or 
2000U/mL of mLIF to these OPC cultures had no significant effect on 
OPC proliferation as assessed by EdU incorporation over 3 hours, 
between 21 and 24h post-addition of mLIF and immediately prior to 
fixation (Fig. 17A). For two of the three experiments, the positive control 
(10ng/mL PDGF) produced a robust increase in proliferation, however in 
one experiment the positive control value showed anomalously low EdU 
incorporation despite other wells, including the normal control, 
appearing normal (Fig. 17A). It is not known what caused this result. The 
trend in these experiments is that LIF increases proliferation, but this is 
not statistically significant, using an ANOVA test. Very high 
concentrations of LIF appear toxic to OPCs. This would mirror what has 
been found by other research groups 156. 
 
 
3.2.2 The T cell secreted cytokine leukaemia inhibitory factor (LIF) does not 
affect microglial proliferation 
 
Introduction 
Since injecting LIF into the site of demyelinated lesions would be 
expected to stimulate LIF signalling in various other cell types besides 
OPCs, the effect of LIF on microglia, found in large numbers at the site of 
demyelinated lesions, was investigated. In response to demyelination, 
microglia are activated and accumulate at the site of injury in large 
67 
numbers. Modifying the behaviour of responding microglia is the focus 
of others in the MS centre, but an indication of the microglial response to 
exogenous LIF would be useful for refining my hypotheses.  
 
Method 
Microglia were obtained as a by-product of the ‘shake-off’ method of 
obtaining OPCs. After separation microglia were placed in 8-well 
chamber slides at a density of 20,000/well and nourished with SATO 
medium supplemented with FGF and PDGF at 10ng/mL concentration. 
After 24h growth factors were withdrawn and LIF was added to wells at 
varying concentrations. After a further 21h of culture 5mM EdU was 
added and the microglia were fixed with 4% paraformaldehyde 3h later. 
After immunostaining for the microglial cell surface marker CD68, the 
nuclei were stained with Hoechst and cells were then imaged with a 
confocal microscope. The images were blind counted and the number of 
EdU-incorporating cells was expressed as a percentage of total CD68 
cells counted.  
 
Results 
The proportion of microglial cells as a percentage of the total number of 
cells in culture was not affected by LIF concentrations of 50, 100, 200, 500 
and 2000U/mL (Fig. 17C). This proportion remained at 75-80% 
regardless of treatment. Although the experiment was only performed 
twice, and so statistical tests cannot be used, there was no effect of LIF on 
microglial proliferation at any concentration (Fig. 17C).  
 
 
3.2.3 The T cell secreted cytokine leukaemia inhibitory factor (LIF) does not 




I went on to apply the same technique to testing whether OPC 
maturation (as defined by MBP expression) is enhanced by the 
application of LIF in vitro. Boosting the number of MBP-expressing cells 
in the context of a demyelinated lesion would be expected to boost the 
chances of effective remyelination, a desirable therapeutic outcome. My 
expectation was that LIF would increase the number of MBP+ cells.  
 
Method 
OPCs were extracted from P0-P2 mice using the shake-off method as 
before. Harvested OPCs were then cultured in 8-well chamber slides at a 
density of 20,000 cells/well. These cells were cultured in SATO medium 
supplemented with FGF and PDGF at 10ng/mL concentration for 24h 
before the media were replaced with SATO containing mLIF at varying 
concentrations. After 72h the cells were fixed with 4% paraformaldehyde 
and immunostained for Olig2 and MBP. Imaging using a confocal 
microscope and blinded counting gave the percentage of Olig2 cells that 
co-expressed MBP at 72h.  
 
Results 
Differentiation, as measured by the percentage of cells which become 
MBP+ after 72h in culture is not significantly affected by the addition of 
LIF to cultures of mouse OPCs. mLIF does not change the proportion of 
oligodendroglial cells in these cultures at 72 hours remaining at around 
60% Olig2+ cells regardless of the culture conditions. Although there is a 
trend increase towards greater numbers of MBP+ cells (typically 0.5-4% 
of the Olig2+ population) at greater concentrations of mLIF, it is not 
statistically significant (using ANOVA) (Fig. 17B). Again the variability 
of values in each condition was large and the low level of MBP 
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expression at 72h in mouse OPCs makes attaining a significant result 
from this experiment technically challenging.  
 
 
3.2.4 The T cell secreted cytokine leukaemia inhibitory factor (LIF) does not 
significantly affect OPC motility 
 
Introduction 
Using a single recombinant cytokine for experiments rather than Treg 
culture supernatant allowed us to test the motility of OPCs. The volume 
of supernatant required for these Transwell experiments made this 
previously unfeasible. I also decided to use rat OPCs rather than the 
more challenging mouse OPCs to assay the effect on LIF on OPC 
movement. Rat OPCs were necessary because of the large numbers of 
cells required. The assay involves placing OPCs on a porous membrane 
in the upper chamber, and placing cell medium containing LIF in the 
lower chamber to set up a chemotactic gradient. The number of OPCs 
that have moved from one side of the membrane to the other at a 
timepoint is quantified, thus determining the motility of the OPCs.  
 
Method 
OPCs were harvested from the CNS tissue of rats by the ‘shake-off’ 
method. The OPCs, plated on the membranes of Transwell inserts at a 
density of 75,000 per well, were nourished with SATO media 
supplemented with increasing concentrations of LIF (500, 200 and 
100U/mL). PDGF at a concentration of 10ng/mL was used as a positive 
control as it is known to increase motility and is chemoattractant to 
OPCs. Cells were left for 16h, a time long enough to determine the effects 
of LIF upon the motility of OPCs without equilibration of the LIF 
gradient. After 16h, the OPCs were fixed with 4% paraformaldehyde and 
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0.01% glutaraldehyde for 30 min and the nuclei were subsequently 
stained with Hoechst dye. Cells on the top of the membrane were 
cleaned away using a cotton bud and those on the underside of the 
membrane imaged and blind counted from a total of 5 images taken from 
each well.  
 
Results 
There was a strong trend towards increased motility in response to LIF at 
the lower end of the range of concentrations used but no statistically 
significant effect (using ANOVA) (Fig. 18). The positive control PDGF 
consistently increased motility and I predict that with more repetitions 
this trend towards increased motility with LIF may become significant.  
 
Summary 
Therefore, from my in vitro assays with LIF, I saw no effect on OPC 
proliferation or maturation, but a trend to an effect on migration. 
However, previous literature has also seen effects on proliferation and 
maturation. This persuaded me that delivery of LIF to OPCs, may be 
useful in vivo to aid remyelination. 
 
3.2.5 LIF-nanoparticle dynamics – pilot study 
 
Introduction 
In collaboration with Dr. Su Metcalfe at the University of Cambridge we 
next sought to test the ability of biodegradable nanoparticles to deliver 
LIF to oligodendrocytes in vivo. Since Treg themselves do not appear to 
be useful for this application, a viable alternative may be to supply 
oligodendrocytes with Treg cytokines through this method. The first 
stage towards accomplishing this goal was to determine the dynamics of 
the nanoparticles in vivo, since I planned to use them to help repair 
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demyelinated lesions.  I obtained these nanoparticles directly from Dr 
Metcalfe, who had manufactured them to contain LIF, (or no LIF as a 
control) and I chose to use nanoparticles coated with the biotinylated 
antibody NG2, to aim to target them to NG2+ OPCs. 
 
Method 
Three groups of 10-week-old mice were used. In the first group of 3 mice, 
I injected 0.01mg of nanoparticles coated with biotinylated anti-NG2 into 
the corpus callosum, and immediately sacrificed the mice, to ensure that 
nanoparticles could be detected. The second group of 3 mice were treated 
identically but perfused after 72h, to determine how long nanoparticles 
were detectable. The third group of 3 mice had demyelinated lesions 
made in the corpus callosum using a 2uL injection of the chemical LPC, 
and 5 days later I injected 0.01mg of nanoparticles coated with 
biotinylated anti-NG2 into the site of the lesion, and culled these 72h 
later. This group was to determine whether nanoparticles either 
accumulated more in such lesions or did not survive such lesions.  
All mice were intracardially perfused under general anaesthetic with 4% 
paraformaldehyde and the brains were removed and post-fixed in 4% 
paraformaldehyde for 24h before being immersed in 15% sucrose solution 
and then 30% sucrose solution 24h later. Brains were then cut in half with 
a coronal section through the site of injection. The rostral and caudal 
sections of brain tissue were then embedded in OCT and 10um sections 
were made using a cryostat. All sections were stained using luxol fast 
blue, in the lesioned brain this was used to locate the lesion and in the 
other two groups simply to visualise the tissue structure and look for the 
site of nanoparticle injection. Nanoparticles were detected by using an 
anti-rabbit fluorescent secondary antibody, as the NG2 antibodies used to 
coat the particles were of rabbit species, and this method had been 




NG2 coated nanoparticles are difficult to detect after injection into the 
CNS. I located the site of injection in the first two groups of animals by 
looking for the needle track in sections but no obvious accumulation of 
nanoparticles was visible, even in the first group. In the third group the 
lesion site was clearly visible on luxol fast blue stains of the corpus 
callosum and yet no nanoparticles were visible. This was surprising since 
the nanoparticles should not have degraded over so short a time-period. 
It may be that the nanoparticles were ingested by microglia or 
macrophages very rapidly and subsequently broken down and this is a 
problem which has been noted previously in the nanoparticle literature 
171. The other possibility is that the nanoparticles quickly entered the 
blood and were cleared from the area of injection. To resolve this issue, I 
propose labelling the nanoparticles directly with fluorescein, to ensure 
easy detection. 
 
Thus, although nanoparticles targeting OPCs are potentially a very 
interesting way to deliver factors locally, and affect OPC function, there 













Chapter 4: Discussion 
 
Here I have presented the results of my project aiming to discover 
whether Treg-derived cytokines, en masse or individually, have 
beneficial effects on CNS remyelination. Although I have been unable to 
prove or disprove this hypothesis conclusively, I have reached several 
conclusions regarding the cytokines that different types of Treg secrete, 
the effect that these cytokines have on OPCs in vitro and the effect of one 
of these cytokines, LIF, has on OPCs in vitro.  
 
 
4.1 Regulatory T cell-secreted cytokines 
 
My aim was to establish the effects of ‘whole’ Treg secretions, rather than 
individual cytokines, on remyelination in the central nervous system, 
with the idea that the cytokines they produced would interact producing 
synergistic or opposing effects which would be impossible to determine 
by examining each cytokine separately.  
One of my first objectives was to establish the composition of these 
secretions, by assaying Treg-conditioned media for known cytokines. I 
had several expectations prior to these assays. I hypothesised that Treg 
cultured in vitro would secrete IL-10 172 and possibly TGFb due to 
previous work demonstrating the immunosuppressive functions of IL-10 
173 and TGFb 174. In my assay, I detected a range of cytokines such as 
IFNg, GM-CSF, IL-4 and TNFa in supernatants from iTreg culture. This 
complement of cytokines agrees with other work from the Anderton lab 
that significant amounts of IFNg and GM-CSF are secreted. Very few 
cytokines were detected in supernatants from nTreg, contrary to 
expectations. The cells used in these experiments were activated in vitro 
via co-stimulation of the TCR and the co-receptor CD28 using activating 
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antibodies, and therefore would be expected to secrete cytokines, 





4.2 Suitability of in vitro culture 
 
Is stimulation in vivo likely to be similar to T cell activation using TCR and 
CD28? 
 
Since the environment of a demyelinated lesion is typically 
inflammatory, I expect that Treg found in this environment will be 




Did contamination by other T cells in culture skew the cytokine results? 
 
I do not believe that there was a significant contamination of the Treg 
cultures by other CD4+ T cells. During the sorting process the CD4+ T 
cells were extracted from whole spleen and lymph node extract using 
MACS. Of this CD4+ population, a well-defined nTreg sub-population 
expressed GFP. This provided a distinct target to sort using FACS 
without the sometimes subjective boundaries between high, medium and 
low expression that some populations of cells require. For iTreg too there 
was a distinct population of GFP+ cells, so it is possible to say with  
confidence that 100% of the plated cells expressed GFP and therefore also 




Do Treg in culture alter their phenotype, hence changing cytokine 
profiles? 
 
There is little or no evidence to suggest that Treg can de-differentiate or 
even ‘trans-differentiate’ into T helper cells under any conditions, so I do 
not expect that any activated T helper cells will have been generated in 
vitro following plating. Furthermore, I tested this hypothesis by isolating 
GFP+ Treg, and quantifying the percentage of cells that retained their 
GFP+ 48 hours, and only saw a minimal reduction in GFP+ cells. 
 
 
Does my Treg cytokine assay fail to identify pertinent cytokines as it 
simply measures concentrations in large volumes of supernatant and 
may not reflect local high concentrations that would occur during close 
cell contact? 
 
One important difference between our in vitro cultures and the in vivo 
situation is the size of the Treg population. From other work in the 
Anderton lab, the population of nTreg in the CNS of a mouse at the peak 
of EAE has been estimated at approximately 1x104 cells. For the purposes 
of my experiment, the Treg were plated, wherever possible, at a density 
of 5x105 per well. This is deliberately high in order to pool the maximum 
number of cells and get the most accurate picture of the secretions from 
these cells. In vivo the concentration of these cytokines would be 
expected to be much lower, but in a much smaller volume than the 2mL 
of medium used in these cultures. However, this large volume of 
medium was necessary for generating the large amounts of supernatant 
to add to oligodendrocytes in vitro. One 2mL well of Treg culture 
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typically provides enough supernatant for applying to only 7 
oligodendrocyte wells.  
 
 
Is there a difference in cytokine production between peripheral blood 
Treg and CNS-residing Treg? 
 
The population of nTreg used in this study is from spleen and lymph 
nodes, and is not antigen specific, as opposed to the myelin-reactive 
CNS-based Treg that would be expected to reside in a demyelinated 
lesion. Unpublished work in the Anderton lab has identified that these 
two subsets of Treg show different gene expression patterns by 
microarray- hence my subsequent interest in LIF, which is expressed 






Does the media used to culture Treg influence their cytokine production? 
 
Initially the two Treg subtypes were cultured exclusively in the 
optimised cell medium for Treg cultures, according to the Anderton lab. 
This includes a relatively high proportion of fetal calf serum (10% b.v.) 
and, to enhance Treg survival, 100 units of activity per ml of the cytokine 
IL-2. Both serum and IL-2 have an effect on oligodendrocyte cell 
processes, such as cell survival, proliferation, and differentiation 3, and 
therefore, using this medium, it would be difficult to identify any 
additional or antagonistic effect of Treg supernatant. For example, in one 
of my early experiments quantifying apoptosis in oligodendrocytes 
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treated either with a vehicle control (Treg medium only containing 10% 
serum and IL-2) or Treg-conditioned medium (also containing these 
components), apoptosis was very low and much lower than normal for 
oligodendrocytes in culture in both groups. Therefore, I attempted to 
culture Treg in serum-free medium, with or without IL-2. This allowed 
Treg media to be added to oligodendrocytes without a great boost in the 
level of serum affecting the results. Two serum-free media were used - 
AIM V, a T cell medium from Gibco, and X-vivo, from Lonza. It is 
possible that these affected the cytokines released by activated Treg in 
culture, and as survival was affected in these suboptimal media, this may 
also have influenced cytokine release and may account for some of the 




4.3 Effects of Treg cytokines on oligodendrocytes  
 
Having generated and analysed supernatants from several different Treg 
cell media I then moved on to testing their effects on oligodendrocytes. I 
tested three different processes in oligodendrocytes that I hypothesised 
would affect the outcome of remyelination; proliferation, differentiation 
and the rate of apoptosis. However, Treg supernatants showed no 
significant benefit to any cell process in oligodendroglial cells in vitro. 
However, I am not fully confident that this finding in my in vitro 
experiments is necessarily secure, due to the following difficulties: 
 
 
Murine OPCs are much more vulnerable than Rat OPCs in culture 
 
78 
The T cells in this project were obtained exclusively from mice, due to the 
ubiquity of transgenic mice in immunology research and my need to use 
GFP to select out Treg. I then applied supernatants to mouse OPCs, but 
extracting OPCs from mouse tissue is more technically challenging than 
rat OPCs. One rat can yield as many OPCs as ten mice, and they are 
cultured more easily. The reasons for this are unclear, and the increased 
size of the rat brain cannot on its own explain the increase in numbers. 
The poor yield and fragile culture of murine OPCs obviously makes 
experiments with these cells proportionally more difficult than using rat 
OPCs, which is the norm in my laboratory. For example, the MBP 
expression of murine OPCs in culture is much reduced and occurs later 
than in rat OPCs. For mouse OPCs, at 72 hours, there are roughly 5% of 
cells stained with antibodies against MBP as opposed to around 20% for 
rat OPCs. This was a source of frustration throughout this project and led 
to an inevitable increase in the variability of such experiments. The low 
yields that come with murine OPCs also make some experiments, such as 
the transwell assay, requiring large numbers of OPCs, unworkable. With 
the move away from ‘whole’ Treg supernatants and towards LIF and LIF 
nanoparticles, the source of OPCs was changed from mice to rats. 
Subsequently the number and quality of OPCs was no longer an issue.  
 
 
Staining to detect differences in differentiation was unreliable 
 
Initially the objective with my differentiation experiments was to try and 
assess both the morphology and the immunomarkers of progressively 
differentiating oligodendrocytes. As oligodendrocytes progress from 
simple, bipolar cells through to highly-branched MBP-positive cells they 
successively express a number of cell surface markers; O4, NG2 and MBP. 
These markers overlap in their temporal expression somewhat. Initially I 
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attempted to classify the stage of each oligodendrocyte’s differentiation 
based on whether they fell into one of five different categories; NG2+, 
NG2/O4+, O4+, O4/MBP+ or MBP+ only. I also intended to quantify 
how the morphology of an oligodendrocyte changes as it matures. 
Sorting cells into three categories; simple, complex and membranous, 
gives another indicator of the level of differentiation in an 
oligodendrocyte population. This technique has been used successfully 
by Huang & Jarjour et al. (2010) to quantify oligodendrocyte 
differentiation. While the immunocytological approach worked well 
occasionally, it was sensitive to poor or non-existent staining in a single 
channel, making such an experiment of little use. The number of 
experiments rendered ineffective by this encouraged me to simplify the 
staining protocol, settling on the reliable MBP staining as a marker of 
what one might refer to as ‘terminally’ differentiated oligodendrocytes, 
which are of the most relevance to successful remyelination. This 
approach was more reliable but no significant effect was observed with 
any of the Treg supernatants tested.  
 
 
Quantification of apoptosis was problematic 
 
For apoptosis, the reliable TUNEL assay was used successfully for every 
assay. Staining from TUNEL was bright, however the morphology of 
apoptotic oligodendrocytes made cell counting tricky. The process of 
apoptosis involves a number of stages where cells take on differing 
morphologies. In the first instance, the cell nucleus, and sometimes the 
cytoplasm, stains brightly. The cell then progressively ‘blebs’ into several 
smaller objects, which in vivo would be phagocytosed by macrophages, 
but in vitro simply degrade slowly over time. Fixation of culture at a pre-
determined timepoints provides a snapshot of the cells apoptosing at that 
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point in time. The problem with counting arises when making a 
subjective decision on whether a group of TUNEL-positive blebs 
constitutes the remains of one or more cells. Most often this is obvious, as 
widely spaced cells in a field of view produce distinct groups of blebs. 
However, in dense groups of cells this becomes more difficult. During the 
process of apoptosis the nucleus is necessarily disrupted too, interfering 
with the localization of the normally reliable oligodendrocyte marker 
Olig2. To overcome these issues two counting methods were used. The 
first was a ratio of the total number of TUNEL-positive objects, including 
each of the blebs in an image, to the total number of nuclei. This removed 
the subjectivity of attempting to decide whether each group of blebs 
constituted one or more cells and also whether any perceived Olig2 
staining was real. Instead this provides an objective measure of the ‘level’ 
of apoptosis in proportion to the overall cell density. This analysis 
assumes that the type of media and Treg cytokines present have no effect 
on the mechanism of apoptosis, for example increasing or decreasing the 
number of blebs produced per cell. The second counting method counted 
the number of objects co-staining for TUNEL and Olig2, with the 
assumption that these constitute the population of apoptosing 
oligodendroglial cells.    
 
 
The Foxp3:GFP mouse has now been shown to have functionally 
defective Treg 
 
One issue that arose during the course of this project concerned the 
transgenic mouse used to obtain the two types of Treg (natural and 
induced) that were used. The foxp3GFP mouse, first generated by 165, 
expresses GFP fused to the amino terminus of the foxp3 protein that has 
been found to be essential for Treg development 114,175,176. Recent work 
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studying the function of foxp3GFP Treg in two mouse models of 
inflammatory autoimmune disease, the K/BxN model of inflammatory 
arthritis and the NOD model of diabetes, have shown that foxp3GFP Treg 
are functionally deficient during inflammation. The fusion of the GFP 
protein to foxp3 appears to lead to steric hindrance that prevents the 
binding of proteins such as Hif1α 177 plus Tip60, HDAC7 and Eos 178. This 
raises the question of whether Treg isolated from foxp3GFP mice in this 
study can be assumed to be ‘normal’ Treg, with a representative cytokine 
secretion profile. Assuming that the mice used in our studies have no on-
going inflammation, a reasonably safe assumption given their 
maintenance in a specific pathogen free (SPF) facility, their reliability 
depends on whether the pathways found to be affected are activated in 
vitro. The signalling pathways most relevant to the in vitro culture of 
iTreg are the IL-2, TGFb, CD28 and TCR pathways. The nTreg used in 
this study were not stimulated with anything other than CD3- and CD28-
activating antibodies so only the TCR and CD28 are relevant to these 
cells.  However, it may be that transgene has the altered physiological 
state of these Treg, which may in part explain the unexpected cytokine 
profile, and means that my findings of the effect of their supernatants on 
OPC behaviour in culture may not necessarily reflect in vivo activity. 
 
 
T lymphocytes prefer different culture media to oligodendrocyte precursor 
cells 
 
An early problem that I encountered in trying to add Treg supernatants 
to OPC cultures was the differing levels of serum content in the standard 
culture media for each cell type. T cells, and Treg, typically grow best in 
cell media containing 10% b.v. fetal calf serum, whereas mouse OPCs are 
best limited to only 0.5% -  any higher and other glial cell types such as 
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astrocytes ‘grow out’ and take over these cultures. Boosting the serum 
content of OPC medium to 5% b.v. by adding Treg-conditioned media 
would be expected to also raise the rate of proliferation and reduce cell 
death to such an extent that detecting a small effect additional effect of 
cytokines in the media could be impossible. Attempts were made to 
culture Treg in serum-free media, firstly AIM V media (Gibco) and then 
finally X-vivo media (Lonza). Initially mixed results with AIM V medium 
led to the use of X-vivo medium, which worked far better. Eventually all 
three media were used in experiments to no effect with the conclusion 
that soluble Treg cytokines have no effect on OPCs in vitro. While this is 
suggestive that the same may be true in vivo, it could be argued that these 
experiments have little relevance to in vivo situations due to the problems 
described above and subsequent evidence as follows. 
 
4.4  Are these results translatable to the in vivo situation? 
 
In MS lesions there are few Treg present 
 
Another consideration in applying the results detailed here to the in vivo 
disease situation in human MS patients is the relative abundance of OPCs 
and Treg within remyelinating MS lesions. It is known that OPCs occur in 
abundance in many MS lesions and that there is a need for factors that aid 
differentiation as these cells appear to suffer from a so-called 
‘differentiation block’ 179. A question that still needs to be answered is the 
abundance of Treg in these same lesions. Histological studies of MS 
biopsy tissue have shown that cells expressing foxp3 are present in early 
MS lesions1. However their density appears to be low, especially 
compared with the numbers of OPCs. The accepted model of Treg 
function in MS suggests that Treg act peripherally and it is not necessary 
for Treg cells to be present in the CNS. Considering the low levels of 
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cytokines secreted in vitro by activated Treg in this study and the low 
density of Treg shown in vivo, it seems unlikely that Treg-secreted 
cytokines alone could have any great effect on the maturity, survival and 
proliferation of OPCs, and thus remyelination. In our LPC model of 
chemical demyelination, we found no foxp3-expressing cells, in contrast 
to studies of human lesions1. As a result, it is unlikely that Treg and OPCs 
interact spontaneously in our model. We attempted to inject Treg into 
these lesions but we concluded that these T cells do not persist for long 
enough following injection in this model.  
 
 
Early post-natal oligodendrocyte precursor cells may respond differently 
than adult OPCs 
 
Some have suggested that remyelination is a recapitulation of 
development, with adult OPCs present in the adult CNS required to 
mature into myelinating oligodendrocytes in order to achieve 
remyelination. In this study, like many others, I used OPCs from the CNS 
of early postnatal mouse and rat pups rather than adult OPCs. These cells 
have a higher rate of proliferation [compared to adult] and typically 
mature in 3-7 days. It is likely that these cells may show different 
behaviours to OPCs present in the adult mammalian CNS. Thus, the fact 
that Treg do not appear to affect important cellular processes in these 
cells does not rule out the possibility that the same cytokines may affect 
the proliferation, maturation and survival of ‘adult’ OPCs.  
 
 




Not much is known about the in vivo physiological or pathological levels 
of the cytokines studied here. Serum measurements of various cytokine 
levels have been taken from MS patients (for example references see 
Kraus, J et al. (2002) 180 and Wang, KC et al. (2013) 181). However, while 
the levels of these proteins at a systemic level may be useful, it does not 
show their varying concentration at a cellular or local tissue level. Thus, it 
is possible that a T lymphocyte secreting molecules either through an 
immunological synapse or into the extracellular milieu of an MS lesion, 
could expose cells to far higher local concentrations.  
 
Due to these problems, I decided to take a candidate approach of 
investigating LIF as a cytokine, which is already known to have an effect 
on oligodendroglial cell biology, and try and deliver it locally to OPCs 
using novel nanoparticle technology.  
 
 
4.5 Why are Nanoparticles interesting tools in CNS remyelination research? 
 
Much attention has been paid to nanoparticle research in recent years 
because of their promise over a range of applications, including targeted 
drug-delivery and possibility to cross the blood brain barrier. In this 
project, I hypothesised that porous nanoparticles containing a Treg-
secreted cytokine, LIF, would, if targeted to OPCs, give a boost to 
remyelination in vivo. Although this strategy is promising, this hypothesis 
relies on several assumptions: firstly, that these nanoparticles successfully 
target OPCs in vitro and vivo, and secondly, that these nanoparticles 
deliver enough LIF to produce an effect. Further investigations need to be 
done to determine whether nanoparticles will indeed be useful. 
With a coating of avidin molecules, biotinylated antibodies can be used to 
target these nanoparticles - in my case, to NG2 molecules on OPCs, as 
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from my experiments and the literature, LIF increases proliferation and 
migration of OPCs in vitro. Experiments to determine whether this 
strategy effectively targeted nanoparticles to OPCs are currently 
inconclusive, but earlier work targeting CD4 molecules on T lymphocytes 
in vivo demonstrates that the principle works 182. However, the 
nanoparticles in this study were injected intravenously. Further work 
needs to be carried out to determine the extent of nanoparticle dispersion 
following injection into the parenchymal tissue of the brain. Previous 
research into the persistence of nanoparticles in vivo has shown that 
phagocytosis by macrophages is the main limiting factor. This has been 
demonstrated in the striatum 183. It will be interesting to see whether 
microglia (the brain macrophages) are equally limiting. Another variable 
is that it is difficult to quantify the quantity of LIF contained in each 
nanoparticle. Attempts have been made to determine this by testing 
media containing LIF-nanoparticles over 7 days. This showed that around 
900pg of LIF was secreted by 1mg of nanoparticles 182 - a very small 
amount - however, it should still be enough to apply a high local 
concentration if the nanoparticle is bound to the cell with antibodies. This 
is the same principle of localised release that the immunological synapse 




4.6  Future work 
 
Following on from this, we will be building on our work on LIF-
nanoparticles, attempting to discover whether they might be useful for 
ameliorating demyelination. Once nanoparticle presence in the brain is 
confirmed, we will inject nanoparticles into demyelinated lesions to 
determine whether remyelination is improved. If this is the case, the next 
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step will be to confirm our hypothesis that LIF is targeting OPCs in the 
environs of the lesion and not other supporting cells, such as microglia. A 
possible method for this is staining for the proteins involved in the LIF-
signalling pathway, such as Stat3. Stat3 is a downstream transcription 
factor that undergoes dimerisation and subsequent phosphorylation on 
LIF binding its receptor. Phosphorylated Stat3 can be detected using 
immunostaining and thus we can determine which cells are activated by 
LIF signalling. There are reliable markers for the three cell types that 
would be of most interest in this respect; OPCs (Olig2), microglia (CD68) 
and astrocytes (GFAP).  
 
Since injecting nanoparticles into the CNS is not a practical delivery 
method in human MS patients, it will be useful to investigate alternative 
methods of delivery. Some nanoparticles have been designed to cross the 
blood-brain barrier, which would be ideal in this situation. These 
nanoparticles, designed primarily to target white blood cells in the 
bloodstream, may be too large to cross the blood-brain barrier efficiently, 
at an average size of approximately 100nm, but this has not been tested. 
However, if they do not, then it may be possible to encapsulate LIF within 
nanoparticles that are smaller. 
If nanoparticles are shown to be useful delivery tools, then other cytokines 
could be added, perhaps even in a sequential way to improve 
remyelination. We know that LIF increases proliferation and migration, 
which would improve OPC recruitment to MS lesions, but other cytokines 
such as 9-cis Retinoic acid or BMP inhibitors may be beneficial for 
promoting OPC maturation if released later in the remyelination process. 
This could be delivered using a separate nanoparticle strategy, or perhaps 
using one nanoparticle which has a differential release rate of different 
cytokines. Therefore nanoparticles may be able to be used as medicine 
delivery systems containing multiple factors released in a sequential way. 
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These are experiments of the future, but with the development of polymer 
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